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Abstract 
Characterization and Quantification of Covalent Modification of Proteins Using Mass 
Spectrometry   
by 
Pratikkumar N Rathod 
Thesis Advisor: Dr. Emmanuel J. Chang 
 Identification and characterization of various post-translational modifications of protein 
is a key to understanding many unknown cellular processes. In the last few decades, mass 
spectrometry has evolved as an essential and effective analytical tool for qualitative and 
quantitative analysis of proteins. In this research, we have developed a novel MALDI-MS
2
 
based quantification method for Desmosine and Isodesmosine, which served as cross-linking 
amino acids of elastin, in order to measure the elastin degradation in the body. This is the first 
quantification method that not only illustrates the potential of MALDI-Ion Trap MS
2
, but also 
improvement over the current LC-MS method, in terms of analysis time and solvent 
consumption, while maintaining similar analytical characteristics. The method is utilized to 
evaluate the time-dependent degradation of Des upon UV radiation (254nm) and result found to 
be consistent with quantification by 
1
H NMR. 
 This work also involves the investigation of potential phosphorylation sites and 
evaluation of its role in various biochemical processes during HIV infection. Based on the 
results from different phosphorylation prediction algorithms, many in-vitro kinase assays were 
performed on HIV-derived peptides/proteins in presence of potential kinases. We have 
successfully identified few novel interactions between host-kinases/HIV phosphorylation 
substrates. These include the interactions of phosphorylation sites of Vif, Nef and Capsid 
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proteins with protein kinase C (PKC), protein kinase A (PKA), and p38 MAPK respectively.  
 Moreover, this work includes the development of cell-active inhibitors for cysteine 
cathepsins, a class of enzymes involve in many important cellular processes and in various 
disorders. In this study, we have synthesized library of two different classes of molecules 
containing oxirane and vinylsulfonate moieties. Various cell-based experiments were conducted 
to successfully demonstrate intracellular inhibition of cysteine cathepsin by these developed 
inhibitory molecules. The result of our study shows 2-(2-ehtylphenylsulfonyl) oxirane is cell-
permeable and irreversible inhibitor of cathepsin B. On the other hand, peptidyl vinylsulfonate 
inhibitor (KD-1) is highly potent and selective cathepsin L inhibitor. 
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1.1 Background 
Mass spectrometry (MS) is a powerful analytical technique that separates ionized 
molecules based on their mass-to-charge (m/z) ratio. The overall process of MS involves the 
conversion of the sample into gaseous ions, separation of gaseous ions based on their m/z 
followed by measurement of current to determine the abundance of ions produced. Mass 
spectrometry is utilized for successful qualitative and quantitative analysis of organic and 
inorganic analytes. Moreover, due to recent advancement, MS has evolved as a method of choice 
for analysis of complex mixture of large biomolecules such as polypeptides and proteins. A mass 
spectrometer, the first of which was developed in 1919 by F.W. Aston [1], consists of a sample 
inlet, an ion source, a mass analyzer, a detector and a data system. The components including an 
ion source, a mass analyzer and a detector are under the vacuum system. 
 
 
Figure 1.1 Schematic representations of the main components of a mass spectrometer 
 
1.2 History 
The current state-of-the-art in MS has been achieved as a result of 120 years of incessant 
developments. A few highlights of this development are listed below: 
1897: Discovery of the electrons and determined its m/z- J.J. Thompson [2] 
1919: Development of first mass spectrometer- F.W. Aston [1] 
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1953: Describe quadrupole & ion trap analyzer in a patent- W. Paul & H. Steinwedel [3] 
1958: Introduction of first commercial LTOF instrument- Bendix 
1974: MS coupled with HPLC- P.J. Arpino, M.A. Baldwin & F.W. McLafferty [4] 
1987: Development of MALDI- T. Tanaka, M. Karas & F. Hillenkamp [5, 6] 
1988: Development of ESI-MS J. Fenn [7] 
1999: Development of the orbitrap- A.A. Makarov [8] 
1.3 Ionization sources 
A prerequisite for successful MS is that the analytes of interest must be in ionized form. 
Furthermore, the ions must be introduced in the gas phase into vacuum system of mass 
spectrometer. The vaporization to the gas phase in vacuum system can be easily accomplished 
for volatile and thermostable analytes while offer difficulties for non-volatile and thermolabile 
analytes. These analytes require either desorption or desolvation methods to be analyzed by MS, 
so called soft ionization. In biological mass spectrometry, the polar and non-volatile 
characteristic of most biomolecules, demand soft ionization methods for MS analysis. Currently 
two vastly accepted soft ionization methods for MS analysis of the biomolecules are, matrix-
assisted laser desorption/ionization (MALDI) and electrospray ionization (ESI). In this research, 
I have employed the MALDI ionization technique for various applications. 
1.3.1 Matrix-Assisted Laser Desorption/Ionization (MALDI) 
MALDI ionization technique was developed by Karas and Hillenkamp in 1987 [5, 6]. 
Since then MALDI is widely accepted and emerge as a powerful tool for MS analysis of broad 
range of large, thermolabile and non-volatile molecules such as proteins, synthetic polymers, and 
organic and inorganic molecules. MALDI utilizes small organic acid molecules as a matrix to 
assist desorption and ionization of the analytes. Importantly, a major advantage MALDI offers is  
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easy sample preparation simultaneously with salt and buffer tolerance [9, 10]. There are mainly 
            
Figure 1.2 Schematic representation of MALDI ionization source 
 
two steps in MALDI analysis. In the first step, the analyte is co-crystallized with molar excess of 
matrix molecules, which usually is small organic acid capable of absorbing laser wavelength. 
While in the second step upon laser radiation under vacuum, the vaporization of matrix 
molecules occur which carry the analyte molecules and result in desorption and ionization of the 
analyte molecules. Thus, matrix play critical role in indirect analyte vaporization and serve as a 
proton donor to assist ionization of the analyte molecules [11].  
The exact mechanism of the MALDI is not completely understood [12, 13]. However, it 
is believed that irradiation of laser results in accumulation of large amount of energy in matrix 
molecules due to rapid heating and lead to sequential processes like, sublimation of matrix 
crystals, ablation of local crystal surface and formation of matrix plume containing intact analyte 
molecules [14]. Various theories have been introduced to explain the ionization process in 
MALDI including, ion-molecule reaction, gas-phase photoionization, excited state proton 
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transfer, and desorption of preformed ions. To date, none of the above processes has been able to 
explain the exact mechanism of the ionization process in MALDI [15]. 
The selection of matrix and optimization of sample preparation protocol are two vital 
criteria in the success of MALDI as ionization source in MS analysis. The important 
characteristics required for an efficient MALDI matrices are- a) high vacuum stability, b) 
capable of absorbing laser wavelength, c) lower molecular mass, d) ability of analyte ionization, 
and e) inert nature. Commonly known MALDI matrix molecules along with the class of analytes 
for which they used for are listed in Table 1.1. A number of sample preparation methods have 
been discussed and evaluated for MALDI MS analysis including thin-layer method [16, 17], the 
sandwich method [18], and dried-droplet method [19].  Among these, the widely accepted 
sample preparation method is the “dried-droplet method”. In this method 1-2 µL of analyte 
solution is mixed with 5-10 µL of matrix solution. 0.5-1µL of this mixture is deposited on 
MALDI-probe; usually consist of a metal plate with regular array for sample application. This 
solution on a metal plate is set at room temperature to dry before the sample is loaded in mass 
spectrometer. 
Due to the incorporation of pulsed laser in MALDI, it produces ions in bundles during 
ionization. Hence, the mass analyzers such as time-of-flight (ToF), fourier transform ion 
cyclotron resonance (FTICR), and ion trap, which are compatible with pulsed ionization, have 
been successfully coupled with MALDI. Additionally, in the efforts to explore a new method of 
injecting ions into ToF, Krutchinsky et al., demonstrated successful application of orthogonal 
injection of MALDI ions to ToF through collision damping interface. This approach makes mass 
measurement process independent of ionization process and enable MALDI source to couple 
with nearly any mass analyzer [20]. These instruments have capabilities to perform MS
2
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analysis, widely utilized in qualitative and quantitative analysis of biomolecules, and offer high 
selectivity and sensitivity. 
   
                 
1.3.2 Electrospray Ionization (ESI) 
The 2002 Nobel Prize Laureate in Chemistry, J. Fenn, has first applied ESI to mass 
spectrometric analysis to measure molecular weight of large molecules in 1988 [7]. As a result of 
many parallel efforts, ESI extended its application beyond protein analysis and demonstrated 
success in analyzing other polymers, as well as small polar molecules. The ESI technique made a 
breakthrough for MS owing to its high sensitivity and ability to readily couple to high-
performance liquid chromatography (HPLC). 
In ESI, the solution of analyte molecules is allowed to pass through a capillary tube. The 
strong electric field obtained by applying a potential difference of 3-6kV between capillary and 
counter-electrode is used to produce electrospray of the analyte solution in ESI [7]. The presence 
Table 1.1 Commonly used MALDI matrices for different analytes 
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Figure 1.3 Schematic representation of ESI source 
 
of an electric field induces a charge accumulation at the liquid surface located at the end of the 
capillary results in formation of highly charged droplets. A coaxial flow of an inert gas at low 
flow rate limits the dispersion space of the spray. To evaporate the solvent molecules from the 
droplet surface, an inert gas flow is directed to the droplets at the spray exit where a “Tylor 
cone” shape is formed. Evaporation of solvent molecules would shrink the droplets and increase 
in charge per unit volume. The breakdown of droplets into small highly charged particles occurs 
when columbic repulsion between the similarly charged molecules is higher than the force of 
surface tension of the droplets. This process continue until only one charged analyte molecule is 
left before entering in mass analyzer. 
 Beside these two widely accepted ionization techniques, there are also few other 
techniques have been evolved in early development stage of mass spectrometry with their unique 
pros and cons. The list of these ionization techniques with their characteristics are stated in Table 
1.2. 
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Table 1.2 List of other ion sources in MS and its specific characteristics 
Ion source in MS Features 
    
Electron Impact (EI) Use beam of electron to form radical cation 
  Advantage 
  Well understood 
  Applied to all volatile compounds 
  Disadvantage 
  Requires thermostable and volatile compounds 
    
Chemical Ionization (CI) Use ion-molecule reaction 
  Advantage 
  Simple mass spectra 
  Disadvantage 
  Thermostable and volatile compounds 
  Less fragmentation- not informative 
    
Fast Atom Bombardment (FAB) Bombarded with fast atom beam (6keV xenon atoms) 
  Advantage 
  Simple, rapid 
  High tolerance to various samples 
  Disadvantage 
  High chemical background at low mass region 
  Analyte must be soluble in liquid matrix 
    
Atmospheric Pressure Use corona discharge 
Chemical Ionization (APCI) Advantage 
  Excellent LC/MS interface 
  Compatibility with MS/MS method 
  Disadvantage 
  Multiply charged species- difficult interpretation 
  Very sensitive to contaminant 
 
1.4 Mass Analyzers 
The separation of generated gas-phase ions in ionization source takes place in mass 
analyzer based on their mass-to-charge (m/z). There are mainly 5 different types of mass 
analyzers: 1) Ion trap, 2) Time-of-flight (ToF), 3) Quadrupole, 4) Fourier Transform-Ion-
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Cyclotron Resonance (FTICR), and 5) Sector (magnetic or electric). As a result of continue 
efforts in mass analyzers development, a new type of mass analyzer, orbitrap, is recently been 
introduced in 2005. All the mass analyzers use static or dynamic electric and magnetic fields 
alone or in combination. These mass analyzers can be classified in mainly two categories based 
on the resolution: a) high resolution analyzer (FT-ICR, ToF and Orbitrap), b) low resolution 
analyzer (Ion-trap and Quadrupole). The performance of mass analyzer is evaluated based on 
following characteristics: i) mass range, ii) the scan speed, iii) the transmission, iv) mass 
accuracy, and v) the resolution. To tackle the current analytical challenges and to improve 
versatility, many hybrid mass analyzers have been recently developed which offer united 
advantage of different types of mass analyzers including, IT-LIT, ToF-ToF, Q-Q-ToF, Q-Q-Q 
and Q-Q-LIT. During my research I have mainly utilized LIT (linear ion trap) and ToF (Time-of-
Flight) mass analyzer for MS analysis. 
1.4.1 Ion-trap analyzer 
 The ion trap mass analyzer separates the gas-phase ions based on their m/z as well as 
store the ions [21]. The ions are trapped in two or three dimensions by oscillating electrical field 
and RF quadrupole field. Hence, ion trap analyzer can be classified in two different types: 1) 3D 
ion trap (Quadrupole ion trap or Paul ion trap), 2) 2D ion trap (linear ion trap). 
 The quadrupole ion trap (QIT), invented by Paul and Steinwedel in early 1950’s [3], and 
is consists of three electrodes: a donut shaped ring electrode is surrounded by two end cap 
electrodes on both sides. Upon the application of RF voltage QIT behaves as an ion storage 
device in which ions are focused in the center of the trap. The motion of ions in the QIT is 
characterized by one radial and one axial frequency. To circumvent the space charging effect 
(only limited number of ions can be stored due to the space charge effect), most QIT instruments 
10 
 
have an automatic gain control (AGC). This feature controls the adequate fill time of the trap to 
enhance sensitivity and to subside resolution losses due to space charge effect.  
 
Figure 1.4 Schematic representation of 3D ion trap (QIT) 
 
To obtain a mass spectrum, mass-selective ejection of ions is required by continuous 
increase in RF voltage at the constant rate, in which ions with lower m/z are ejected first. 
Because resolution of the spectrum strongly depends on the speed at which the RF voltage is 
increased, higher resolution is attained with slower speed. Comparatively high sensitivity can be 
obtained using QIT due to the ability of ion accumulation in the trap. In principle, QIT can 
perform in time MS
2
 and produce fragment ions using neutral gas molecules such as helium, 
nitrogen or argon. 
 The 2D ion trap, also known as linear ion trap (LIT), is one of the recently developed 
mass analyzer, introduced by Schwartz in 2002 [22]. Physically, a linear ion trap is similar to a 
quadrupole analyzer but in principle it is alike QIT analyzer. LIT is formed by four hyperbolic or 
circular rods arranged symmetrically that can be divided into three compartments: a) front, b) 
11 
 
central, and c) back compartment. The ions are confined radially by a two-dimensional RF field 
in LIT.  
 
Figure 1.5 Schematic representation of 2D ion trap (LIT) 
 
DC voltage is applied to the front and the end compartments to prevent the axial ion 
escape from the LIT. Application of DC voltage repels the ions from both ends and focus 
towards the central compartment of the LIT. However, both 3D ion trap and 2D ion trap can be 
applied to similar type of mass analysis, 2D ion trap offers following advantages over the 3D ion 
trap: 1) higher ion trapping capacity (due to the ions are focused along the center line rather than 
to a point), and 2) higher ion trapping efficiency. Because the ions are ejected radially through 
the slits of the rods from central compartment, placement of two detectors axially on both side of 
the rods are essential to maximize sensitivity of the LIT. 
 1.4.2 Time-of-Flight (ToF) mass analyzer 
 Time-of-flight (ToF) mass analyzer separates the ions based on the time required to cross 
the field free region, known as flight tube, after initial acceleration by an electrical field [23]. 
ToF analyzer is well suited for pulsed nature MALDI ionization source. As kinetic energy is 
12 
 
distributed equally among the ions in ToF, the separation of ions is based on the velocities of the 
ions. Hence, the time required for the ions with lower m/z is shorter than ions with high m/z to 
 
Figure 1.6 Schematic representations of linear ToF and reflectron ToF analyzer [24] 
 
 travel to the detector. Owing to the good transmission, a spectrum over wide mass range can be 
generated in short time using ToF analyzer. Moreover, in principle ToF analyzer does not have 
any upper mass limit; the mass range is mainly limited by decrease in detector response with 
increase in m/z. The mass resolution of simple ToF mass analyzers is relatively poor due to the 
energy distribution of the similar m/z in the flight time. This issue can be addressed either by 
reducing kinetic energy distribution of ions before application of acceleration voltage or by 
increasing the length of the flight tube.  
One of the approaches, to reduce the kinetic energy distribution of the ions, is the 
introduction of time delay between the ionization and acceleration voltage, also known as 
delayed pulsed extraction. The time delay is generally range from ns to µs before the application 
of acceleration voltage. An optimum delayed time can compensate for ion energy distribution 
13 
 
and improve mass resolution in ToF analyzer. Another approach to improve the mass resolution 
of ToF analyzer is by introducing an electrostatic mirror in the drift region to significantly 
improve the path length for ion travel. In this set-up, the ions with high energy penetrate deeper 
in the electrostatic mirror region compare to the ions with similar m/z but carry less energy. As a 
result, all the ions with similar m/z reach at the detector at the same time which reduces the 
energy distribution. This modification in ToF analyzer not only increases the mass resolution by 
increasing in the flight path but also maintain the compact size of the instrument. Mostly all the 
commercial ToF instruments have two detectors (one for linear mode and one for reflectron 
mode). 
 
 
1.4.3 Hybrid mass analyzer 
The hybrid mass analyzer is a combination of one or more type of mass analyzers. The 
hybrid analyzer offers the combined pros of different mass analyzers in one instrument at a time. 
The most common mass analyzers involved in development of the hybrid ones are: quadrupole 
(Q), ion trap (IT), linear ion trap (LIT), time-of-flight (ToF), and ion cyclotron resonance (ICR). 
The first hybrid mass analyzer, Q-Q-Q, was developed by Yost and Enke in 1978 led to 
development of series of hybrid mass analyzers [25]. The hybrid analyzer offers excellent 
Table 1.3 List of characteristics of various mass analyzers [24] 
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platform for MS
2
 or even MS
n
 analysis, in addition to, excellent dynamic range, high resolution 
power, and high mass accuracy. The hybrid mass analyzers which have successfully established 
their importance through their performances are listed in Table 1.4. 
 
         
Note: +, ++ and +++ mean moderate, good and high respectively [26] 
 
1.5 Tandem mass spectrometry 
 Tandem mass spectrometry (MS
2
) is two or multistage mass analysis that involve some 
type of dissociation process to generate the fragment ions from the mass-selected ions. The 
tandem mass spectrometry is an excellent tool for determination of peptide/protein sequences, 
identification of analytes, structure elucidation and quantification through fragment fingerprint. 
In principle, the tandem mass spectrometry can be conceived in two ways: a) in space by the 
coupling of two distinct mass spectrometers, b) in time by performing appropriate sequence of 
events in an ion storage device. The mass spectrometers capable of in space tandem mass 
analysis utilize magnetic sector, quadrupole and ToF/ToF mass analyzers. On the other hand, 
tandem mass spectrometry can also be achieved through time separation using the mass 
analyzers such as ion trap, orbitrap and FTICR.  
Table 1.4 Performances comparison and characteristics of various hybrid analyzers 
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 There are main three types of scan modes available using tandem mass spectrometry that 
utilize inert collision gas for fragmentation: 1) product ion scanning, 2) precursor ion scanning, 
and 3) neutral loss scanning. 1) Product ion scanning is the most common MS
2
 experiment for 
identification of the amino acid sequence of specific peptides/proteins. In product ion scanning, 
the first analyzer (MS1) is set to a value that selects one specific precursor ion at a time. The 
selected ion undergo collision-induce dissociation (CID) in the collision cell, and resulting 
fragments are analyzed by the second analyzer (MS2). 2) Precursor ion scanning sets the second 
analyzer (MS2) to transmit only one specific fragment ion to the detector while MS1 is scanned 
to detect all the precursor ions that can generate this specific fragment ion. This mode is used to 
detect a subset of peptides in a sample that contain a specific functional group such as phosphate 
ester. 3) Neutral loss scanning scans both analyzers in a synchronized manner, so that the mass 
difference of the ions passing through MS
1
 and MS
2
 remains constant. The common application 
of this scan mode is the detection of peptides phosphorylated at serine or threonine residue via a 
loss of phosphoric acid. 
The most commonly used MS
2
 activation method is collision-induced dissociation (CID), 
in which collision of selected precursor ion with inert gas, such as helium, results in 
fragmentation of the mass-selected ion. Beside CID, there are various activation approaches are 
developed and/or under investigation such as electron capture dissociation (ECD) [27, 28], 
electron transfer dissociation (ETD) [29], infrared multiphoton dissociation (IRMPD) [30], and 
surface-induced dissociation (SID) [31]. The development of alternative activation approaches 
helps to better understand the unimolecular dissociation behavior of a molecule under different 
excitation methods.  The activation methods such as CID and IRMPD are based on vibrational 
activation, in contrast to ECD and ETD, which are based on radical-induced dissociation.  
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Figure 1.7 Various tandem mass scanning modes- product ion scan, precursor ion scan, and neutral loss      
                 scan. 
 
 Peptide sequence identification using MS
2
 involves fragmentation of a peptide to produce 
smaller m/z fragment ions, which are assemble together to determine the original peptide 
sequence. Depending on the cleavage of different bonds along the peptide backbone, different 
types of fragment ion are produced as shown in Figure 1.8 below. These fragment ions are 
labeled as a, b or c ions if the charge is retained by N-terminal fragments and as x, y or z ions if 
 
 
Figure 1.8 Fragmentation of different bonds along peptide sequence 
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the charge is retained by C-terminal fragments. Among these fragment ions b and y ions are 
considered to be the most useful and abundant fragment ions as they correspond to cleavage of 
amide bond. Interestingly, both fragment ions of a complementary pair are not always detected in 
equal abundance owing to their difference in stability and instrument discrimination. 
1.6 Application of mass spectrometry 
 The basic principle of mass spectrometry is to ionize the sample and measure m/z of the 
resulting ions. The qualitative and quantitative analytical capabilities of mass spectrometry 
efficiently provide information of chemical composition of organic and inorganic compounds. 
Over the last few decades, mass spectrometry has evolved as a vital tool for analysis of various 
biomolecules such as peptides/polypeptides, proteins, oligosaccharides, nucleotides etc. The 
application of mass spectrometry can be classified mainly into two categories: a) qualitative 
analysis, and b) quantitative analysis. 
1.6.1 Qualitative MS analysis 
 Over the last few decades, the mass spectrometry has evolved as an essential tool for 
proteomics. The protein analysis can be performed by two approaches using mass spectrometry, 
“top-down” and “bottom-up”. In top-down approach, the intact proteins are introduced in MS 
without proteolytic digestion and are fragmented into smaller peptides in mass spectrometer. Due 
to complex isotopic distribution patterns of high mass proteins in top-down approach, it requires 
high resolution mass analyzer. Also, employment of ESI in top-down approach can result in even 
more complex mass spectra due to the presence of multiply charged ions.   
In contrast, the bottom-up approach involves the use of proteolytic digestion of intact 
proteins to produce fragment ions before MS analysis. In bottom-up approach, the identification 
of protein is performed from measurement of peptides mass generated from protein digestion, 
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also called peptide mass fingerprint (PMF) followed by comparison with a sequence database. 
Moreover, MS
2
 analysis can determine the amino acid sequence of each peptide to aid protein 
identification.   
 The activation and function of a protein is largely dependent on the post-translational 
modification. Among many covalent modifications, phosphorylation, glycosylation, and 
ubiquitination are the most common ones. In order to characterize the protein, it is essential to 
study these changes in the protein structure. Due to the recent advances in mass spectrometer 
instruments, MS analysis has replaced many conventional approaches to study protein 
modifications, for example, MS analysis overshadows the use of radioactive labels and Edman 
sequencing to study protein phosphorylation over the last two decades.  
Beside identification and characterization of proteins, mass spectrometric analysis can 
also apply to determine chemical structure and chemical formula of small organic compounds. 
Moreover, the role of mass spectrometry has recently evolved in study of drug metabolism due to 
the availability of high resolution mass analyzers such as FT-ICR and orbitrap. The MS analysis 
assists to identify the primary metabolites and to determine pharmacokinetic parameters based on 
in vitro and in vivo drug metabolism study [32].  
1.6.2 Quantitative analysis 
As a result of many technological advances in mass spectrometer in last few decades, the 
application of mass spectrometry has not been restricted to successful identification of proteins 
or protein complexes but has been extended to quantitative proteomics. Quantitative proteomics 
is critical for understanding protein kinetics and molecular mechanism of biological processes. 
Although, MS lacks inherent quantitative analysis capabilities due to different ionization 
efficiency of many peptides and variation in mass spectrometric response of proteolytic peptides 
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between runs, many approaches have been developed to overcome this limitation such as label 
free quantification, metabolic labeling, isotope tags, and isobaric tags. MS-based quantitative 
proteomics can be divided into two categories: a) relative quantification, and b) absolute 
quantification. In relative quantification approach, the samples are differentially labeled with 
stable isotopes. These samples are mixed together followed by quantitative MS analysis. 
Generally, peak intensity ratios of differentially labeled peptides (light and heavy) are measured 
to quantitate the relative abundance. Many isotope-based quantification methods have been 
developed such as metabolic labeling (SILAC) and enzymatic or chemical labeling.  
In absolute quantification, the experimental samples are spiked with the known 
concentration of isotope-labeled target peptides. Hence, the abundance of the target peptides is 
determined by comparing the abundance of the isotope-labeled target peptides. Although, 
absolute quantification method seems more obvious, but in routine, relative quantification 
approach is more often used due to requirement of costly reagent and time-consuming assay 
development for the absolute quantification of each protein of the interest. 
1.6.2.1 Label-free MS quantification 
 In label-free MS quantification method, samples are separately prepared and analyzed by 
MS or MS
2
 because of which this approach is more prone to experimental variations than all 
other quantification methods. Label-free MS quantification method is cost effective and rapid 
compared to other quantification methods. Hence, it is an ideal approach when large numbers of 
samples need to be analyzed such as in clinical screening. However, this method is good for 
measuring large changes in proteins and less efficient in measuring small changes. Using label-
free approaches, the abundance of proteins or peptides can be determined by two ways: a) based 
on ion peak intensity, and b) based on spectral counting. In the former method, relative 
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quantification of similar peptides between samples is determined directly from the mass 
spectrometric ion peak intensities, while in later method; the sum of MS
2
 spectra of LC-MS run 
of a peptide across different samples is utilized to determine the abundance of a protein. 
 
Figure 1.9 Workflow of various proteomics quantitative approaches [35] 
 
1.6.2.2 Isotopic labeling 
 The isotopic atom or isotope-coded tags can be introduced to the sample by various 
means like metabolic labeling, enzymatic labeling and chemical labeling. Metabolic labeling for 
relative quantification was first introduced by Oda et al., who labeled all amino acids with heavy 
nitrogen (
15
N) [33]. This approach was further developed by Mann et al. and introduced as stable 
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isotope labeling by amino acids in cell culture (SILAC). Nowadays, SILAC has evolved as the 
most common approach for in vivo labeling [34]. In SILAC, in contrast to initial approach, cells 
are now grown in growth medium containing 
13
C6-lysine and/or 
13
C6-arginine. These residues 
were chosen so that after trypsin digestion all the peptides contain at least one labeled amino acid 
and result in constant increase in mass of labeled samples compare to non-labeled sample. 
Among many advantages of this approach, the key advantage is, as non-labeled (light) and 
labeled (heavy) samples are combined before sample preparation for MS analysis, the possible 
experimental bias is minimum compare to all other quantification approach. Additionally, this 
approach can successfully detect the small changes in a protein between different experimental 
samples. Other approaches like enzymatic labeling and chemical labeling find their application 
especially for various biological samples where metabolic labeling approach is not amenable. 
The isotope labeling can be achieved by different means such as 
18
O [36], 
2
H [37], stable isotope 
dimethylation [38], Isotope-coded affinity tag (ICAT), and isotope-coded protein labeling 
(ICPL). The ICAT method employs a reagent, which is comprised of three different regions, a 
sulfhydryl-reactive group, a linker region (heavy or light), and a biotin molecule. Due to the 
presence of sulfhydryl-reactive group, the ICAT reagents react only with free thiol on cysteine 
residues.  
 
Figure 1.10 Structure of ICAT reagent [39] 
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Owing to the characteristic of only labeling cysteine residues in experimental sample, this 
approach offers unique capability to minimize sample complexity and assist in identification of 
low-abundance proteins from the samples [40]. These labeled cysteine containing peptides from 
an experimental sample are then separated from non-labeled peptides by passing this sample 
through immobilized avidin, which binds to the biotin tag. Another approach based on the 
isotope labeling is isotope-coded protein labeling (ICPL), in which lysine residues and available 
N-termini are isotopically labeled.   
1.6.2.3 Isobaric labeling 
 The isobaric tags are also known as tandem mass tags as isobaric labeling method 
requires tandem mass spectrometry for quantification. The isobaric tags generally comprise of 
three components, a) a mass reporter- has variable number of stable isotope substituted atom, b) 
a mass normalizer- has unique mass to balance the mass of all the isobaric tags to equal mass, 
and c) a peptide reactive group- react with primary amine or cysteine residues of the 
experimental samples. 
 
Figure 1.11 Structure of Isobaric mass tag [41] 
 
 These isobaric tags are developed in a way that a mass reporter falls off from each 
labeled peptide upon collision-induced dissociation (CID) during MS
2
 analysis and yield 
different size tags. The relative quantification of peptides is performed by quantifying these tags 
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[42]. The examples of commercially available isobaric tags are iTRAQ and TMT, which can 
simultaneously analyze 4 to 8 experimental samples. Owing to the multiplex capabilities, high 
throughput quantitative analysis is possible using the approach. 
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2.1 Introduction 
Elastic fibers represent the major structural component of the vertebrate extracellular 
matrix (ECM) assemblies. The prime importance of elastin, a principal component of elastic 
fibers, is to impart elasticity and resilience to a range of tissues. The elastin contributes to the 
structural foundation of lung [43], skin [44], aorta [45], bladder [46] and female reproductive 
tract [47] and play critical role to maintain shape and normal physiological functions of these 
tissues. Elastin is a highly insoluble polymer protein consists of the cross-linked, soluble 
monomeric precursor molecule called tropoelastin [48, 49]. Tropoelastin is 60kDa 
unglycosylated protein encoded by a single human gene and secreted by various cells including 
fibroblasts [50], smooth muscles cells [51], chondrocytes [52], and endothelial cells [53]. 
The tropoelastin, a building block of elastin, is mainly cross-linked by two polyfunctional 
amino acids [54]. The scientists named J. Thomas, E. Eldsen, and M. Patridge have pioneered 
the study of the cross-linking in elastin. They published the first report in 1963 on the isolation of 
                         
Figure 2.1 Structure of desmosine and isodesmosine. 
the cross-linking amino acids from bovine ligamentum nuchae and named them as desmosine 
and isodesmosine [54, 55]. Subsequently, as a result of their study to understand the biosynthesis 
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of these two amino acids, Anwar and Oda [56] found that these amino acids, desmosine (Des) 
and its structural isomer isodesmosine (Isodes) are originated from the condensation of four 
lysine amino acid residues [57-59]. 
The cross-linked tropoelastin is known as mature elastin, which is mainly produced in 
early stage of the life. The mature elastin is the longest lasting protein in the body with half-life 
of about 74 years [60]. However, in the event of damage to the elastin in the skin due to serious 
injury, sun burn or as a result of aging, the low level of elastin production results in loss of the 
elasticity or inefficient repair. Moreover, the elastin degradation products activate the elastin 
receptors, which subsequently stimulate elastase and lead to further degradation of mature 
elastin. Hence, many serious pathological disorders are associated with degradation of elastin. 
Since desmosine and isodesmosine are unique to the mature elastin, the presence of these amino 
acids in various body fluids including urine, plasma or sputum is considered as a potential 
biomarker for the diseases associated with elastin degradation. Consequently, many reports have 
been published in last few decades using various analytical techniques to quantify these amino 
acids to measure elastin degradation. 
2.2 Pathological disorders 
 As elastin is responsible for functionality of many connective tissues, various 
pathological conditions arise due to the abnormality in elastin (either accumulation or 
degradation). The evidence suggests that in various destructive lung disorders such as chronic 
obstructive pulmonary disease (COPD), disseminated bronchiectasis and cystic fibrosis (CF), the 
degradation of elastin occur due to imbalance between elastin-degrading proteases and protease 
inhibitors. [61-63]. The pathological conditions associated with elastin can be categories by two 
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distinct approaches. A) Based on their occurrence on deposition or degradation of elastin. The 
disorders such as atherosclerosis, abdominal aortic aneurysms, cutis laxa, anetoderma, 
pulmonary emphysema, chronic pulmonary obstructive disease (COPD), marfan syndrome and 
menkes’ syndrome are associated with degradation of elastin in the body. In contrast, 
scleroderma, endocardial elastofibrosis, pseudoxanthoma elasticum (PXE), elastomas, and 
buschke-ollendorff syndrome are the result of accumulation of elastin. B) Based on the inherited 
and acquired diseases. For e.g. marfan syndrome and buschke-ollendorff syndrome are inherited 
elastin associated disease. On the other hand, elastomas and actinic elastosis are acquired elastin 
associated conditions.  
2.3 Quantification methods 
Studies have shown a correlation between the amounts of Des/Isodes detected in human 
body fluids with the degree of elastin degradation [64-66] and therefore, Des/Isodes have been 
considered as potential biomarkers to determine the extent of tissue damage and elastin 
breakdown. This is due to Des and Isodes being uniquely associated with mature elastin, not 
being metabolized after being released from tissue [67] and being independent from the diet [68]. 
A wide range of analytical techniques have been applied to detect Des/Isodes, which include 
enzyme-linked immunosorbent assays, [69, 70], amino acid analysis [71], radioimmunoassay, 
[72, 73], electrokinetic chromatography [74], electrophoresis [75, 76], Nuclear Magnetic 
Resonance, NMR [77, 78],  high performance liquid chromatography, HPLC [79-82], liquid 
chromatography-mass spectrometry, LC-MS and LC- tandem mass spectrometry, LC-MS/MS 
[83-85]. Among these methodologies, reported results show that LC-MS/MS gives the greatest 
selectivity and sensitivity for Des samples where Des detection limits on the order of 10
-9
 M 
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have been obtained [71, 86]. One of the most recent techniques incorporating LC-MS to 
determine Des/Isodes amounts involve the use of deuterated Des as an internal standard [86, 87]. 
Ma et al. results, incorporating the quadruply deuterated (d4)-labeled-desmosine as an internal 
standard, demonstrated the concentrations of total Des + Isodes and free Des + Isodes in plasma 
were 0.51 and 0.09 ng/mL, respectively [86]. Another study conducted by Albarbarawi et al. to 
investigate total Des/Isodes content was performed on COPD urine samples utilized d5-Des 
internal standard. The data showed COPD patients on average (20.4 ng Des/mg creatinine) had 
three times the total amount of Des/Isodes than healthy patients (6.8 ng Des/mg creatinine) [87]. 
 Beside the advantages, there are some challenges in analysis of Des/Isodes with LC-MS 
such as relatively long chromatography runs as well as the labor-intensive process to prepare 
samples. One potential analytical technique to improve the Des/Isodes analysis times while 
maintaining sensitivity and selectivity is to use Matrix Assisted Laser Desorption/Ionization-
Mass Spectrometry (MALDI-MS). MALDI ionization has the benefit of rapid analysis times 
without the requirement for chromatographic separation. 
2.4 Development of rapid and sensitive quantification method for desmosine using MALDI-
LTQ 
In the present report, we have developed a MALDI-MS
2
 based quantification method to 
study Des samples mixed in serum or urine. The approach involves synthetic stable-isotope 
labeled d4-Desmosine (Labeled-Des) as an internal standard to quantify Des and Isodes by 
selectively monitoring an ion that arises from the removal of one of the side chains [M- 
CH2CH2CH2CH2CH(NH2)COOH]
+
, (130 Da). In the linear ion trap mass spectrometer, this 
transition yields a specific and sensitive method for the detection and quantification of Des and 
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Isodes. In this study, the efficacy of the methodology is determined by evaluating linearity, 
detection limit, and run-to-run reproducibility of Des, Isodes, and 50:50 Des/Isodes mixtures in 
water, as well as in backgrounds of serum and urine. Furthermore, we have quantified time-
dependent degradation of Des upon UV radiation using MALDI-MS
2
 and discuss the results in 
comparison to 
1
H NMR.  
2.4.1 Materials and Methods 
2.4.1.1 Chemicals 
HPLC grade acetonitrile and water were purchased from Fisher Scientific (Pittsburg, PA, 
USA). Trifloroacetic acid was purchased from Thermo Scientific (Rockford, IL, USA). α-cyano-
4-hydroxycinnamic acid (CHCA) and deuterium oxide (D2O) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Des and Isodes standards were obtained from Elastin Products 
(Owensville, MO, USA). Stable-isotope labeled desmosine standard was obtained from Toronto 
Research Chemicals (North York, ON, CANADA). Calf serum and human urine was obtained 
from healthy donors and sterile-filtered before use.  
2.4.1.2 Mass spectrometry 
Samples were analyzed using Thermo LTQ XL linear ion trap mass spectrometer 
equipped with a vacuum MALDI source utilizing a nitrogen laser (337 nm) firing at 60 Hz 
(Thermo Scientific, Waltham, MA, USA). A saturated solution of α-cyano-4-hydroxycinnamic 
acid (CHCA) was prepared using the dried droplet method as described as previously described 
[88], and was used as a matrix solution. MALDI-MS
2
 experiments were performed in positive 
ion mode using 3.0 µJ laser energy. Mass spectra of samples were typically obtained using 400-
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600 scans (3-5 minutes) and processed with Xcalibur (2.0.7 SP1) software. Current study 
involves the use of isotope-labeled internal standard (Labeled-Des) for quantification of Des and 
Isodes. To study relative abundance of Des or Isodes in samples, the ratio of the generated 
fragment ion, 397 m/z (Des or Isodes) to 400+401 m/z (Labeled-Des) were utilized. The 
precursor ion (m/z 528), with isolation width of 6 Da, was chosen to perform MS
2
 experiment of 
Des or Isodes standard (m/z 526.2) mixed with Labeled-Des standard (m/z 530.2). Fragmentation 
of precursor ion was conducted with normalized collision energy 36, activation Q 0.25 and 
activation time 30 ms. 
2.4.1.3 UV-irradiation of Des 
The sample, prepared by dissolving Des in D2O solvent, was subjected to UV radiation 
using 12 low pressure mercury lamps of 254 nm in a Rayonet Photoreactor. UV-irradiated Des 
sample was analyzed using mass spectrometry (MALDI-MS
2
) and 
1
H NMR at different time 
intervals (0, 5, 15, 30, and 60 min). The enclosed system was used during UV-irradiation to 
ensure that Des sample was solely exposed to the specific wavelength of UV light.  
2.4.1.4 Proton NMR 
Liquid state 
1
H NMR spectra were recorded using Bruker DPX 400MHz FT NMR with 
automatic sampler. NMR spectra were acquired by accumulating 160 scans and chemical shifts 
(δ) were reported in parts per million (ppm). The peak at 8.44 ppm was observed in non-
irradiated as well as UV-irradiated Des sample, was integrated in reference to the aliphatic 
region (1.00-5.25 ppm). The relative concentrations of Des were calculated from integration 
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values of a peak at 8.44 ppm for different time intervals and used to determine the rate constant 
of UV-induced degradation of Des.  
2.4.1.5 Sample preparation for detection limit study in urine and serum 
To assess the detection limit of Des, an initial concentration of Des was prepared using 
urine and serum, using sterilized human urine from healthy donors and commercially prepared 
newborn calf serum without further dilution or purification. Successive dilutions of Des samples 
were prepared using HPLC-grade water. 1 µL of analyte solution was mixed directly with 9 µL 
of CHCA matrix solution without prior enrichment. For mass spectrometric analysis 1 µL of this 
mixture was deposited onto a stainless-steel plate using dried droplet method. 
2.4.2 Results and Discussion 
The amounts of Des/Isodes have been shown to be elevated in many pathological 
disorders associated with elastin degradation [86, 87]. Consequently, there is a need for simple, 
reliable and sensitive methods to quantify low levels of Des and Isodes. The present study 
introduces a MALDI-ion trap MS
2
 based quantification method for detection of Des and Isodes. 
Labeled-Des is employed as an internal standard for quantification of Des and Isodes. Due to low 
abundance and poor signal-to-noise of the precursor ion of Des (m/z 526.2) and Labeled-Des 
(m/z 530.2), single-stage MS analysis is inefficient to measure quantitative changes in the 
samples (data not shown). Consequently, quantification is performed using the stable fragment 
ion (m/z 397) generated by removal of one of the side chains from Des molecule [M- 
CH2CH2CH2CH2CH(NH2)COOH]
+
, 130Da, in tandem-MS mode. Linearity, dynamic range, 
detection limit and reproducibility of the MALDI-MS
2
 method in water and body fluids are 
32 
 
presented in this report. To demonstrate the application of MALDI-MS
2
 method, quantification 
of Des degradation upon UV radiation (254nm) at different time points is studied using both 
MALDI-MS
2
 method and NMR spectroscopy. 
2.4.2.1 MALDI-MS
2
 analysis of Des, Isodes and Labeled-Des 
Mass spectrometry is an analytical technique that separates ions based on their mass-to-
charge (m/z) ratio. MALDI-mass spectrometry utilizes a small organic molecule (CHCA) as a 
matrix to assist in the energy transfer and ionization process of the analyte. Due to high 
background resulting from ions produced from matrix molecule itself, the precursor ions 
generated from Des samples were difficult to detect in single-stage MS. Therefore, MS
2
 spectra 
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Figure 2.2 MALDI-MS
2
 analysis of Des, Isodes and Labeled-Des- (A) MS
2
 spectra of Des, Labeled-Des 
and Isodes are shown in a top, middle and bottom panel respectively. The highlighted fragment ions 
resulted from loss of a side chain of Des and Isodes (m/z= 397), and Labeled-Des (m/z= 401) were used 
for the quantification of Des/Isodes. (B) Isotope distribution of the fragment ion (m/z= 401) of Labeled-
Des and the fragment ion (m/z= 397) of Des/Isodes are shown in blue and orange respectively. The result 
shows two major isotope peaks, 400 m/z and 401 m/z, represent greater than 75 percentage of total peak 
area of the fragment ion (m/z= 401). 
 
of the two structural isomers were then evaluated. The results showed both structural isomers 
indeed produce similar fragment ions. However, substantial differences in intensity of the 
fragment ions were observed. MS
2
 spectra of both structural isomers and Labeled-Des that used 
as an internal standard to quantify Des, Isodes and equimolar mixture of Des + Isodes are shown 
in Figure 2.2A. 
Since labeled-Des was employed as an internal standard, it was important to evaluate its 
isotopic purity. To do this, the isotope distribution pattern of one of the most abundant fragment 
ions generated from Labeled-Des was evaluated. The selected fragment ion, 401 m/z, was 
generated from loss of one of the side chains, [M- CH2CH2CH2CH2CH(NH2)COOH]
+
, of 
Labeled-Des molecule. (Figure 2.2B) The result of isotopic distribution pattern showed two 
major isotope peaks, 400 m/z and 401 m/z, representing greater than 75 percentage of total peak 
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area of the fragment ion. Hence, to compensate for isotopic impurity, instead of incorporating 
peak area of any single isotope peak, we decided to incorporate the peak area of two most 
abundant isotope ions (m/z = 401 and 400) of Labeled-Des in this investigation. To quantify 
Des/Isodes, peak area ratio fragment ions generated from Des/Isodes (397 m/z) to Labeled-Des 
(400+401 m/z) is determined. Linearity, detection limits and reproducibility have been evaluated 
to assess the applicability, sensitivity and efficacy of the presented MALDI-MS
2
 quantification 
method. As detection of Des and Isodes in different body fluids can be used as biomarkers for 
elastin degradation in body, we have evaluated these parameters in urine and serum. 
2.4.2.2 Linearity and dynamic range 
To evaluate the linearity of the MS response, 11 different concentrations of Des range 
from 125 ng/µL to 3.125 ng/µL were mixed in a 1:1 (v/v) ratio with 25 ng/µL of Labeled-Des. 
Two sets of each of these mixtures were analyzed in quadruplicate. The linear curve was 
obtained by plotting the average peak area ratio of Des/Labeled-des vs. concentration of Des. 
Linear response of Des using Labeled-Des (r
2
= 0.998) over two orders of magnitude was 
obtained as shown in Figure 2.3A. Inter-assay precision (%RSD) obtained using MALDI-MS
2
 
method was from 0.17% to 4.7% for the entire dilution range.  
A response curve for Isodes was generated for similar concentration range as of Des. 
Linear response (r
2 
=0.998) was also obtained from response curve of Isodes (Figure 2.3B). Each 
of these dilutions was analyzed in quadruplicate. Moreover, , because in vivo, Des and Isodes 
occur in equimolar amounts [89], we mimicked this condition by investigating equimolar 
concentration ratios of Des and Isodes. These were studied over a concentration range of 125 
ng/µL to 3.125 ng/µL mixed with 25 ng/µL of Labeled-Des. A linear response with r
2
 value of 
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0.998 was obtained for equimolar ratio of Des and Isodes as shown in Figure 2.3C. We note that 
quantitatively reproducible differences in MS
2
 fragment intensities could in principle be used to 
independently quantify Des and Isodes; however prior studies indicate that using the combined 
concentration of Des and Isodes give a better assessment of elastin breakdown [87]. 
 
Figure 2.3 Linearity of Des, Isodes and equimolar concentration ratio of Des: Isodes were evaluated 
using MALDI-MS
2
 quantification method. Linearity of MS response over the dynamic range from 125 
ng/µL to 3.125 ng/µL are shown for- Des (A), Isodes (B), and equimolar concentration ratio of Des: 
Isodes (C). Linearity of Des was also assessed in biological fluids- serum (D), and urine (E) over the 
dynamic range from 43.75 ng/µL to 6.25 ng/µL. 
 
Furthermore, the linearity of Des response in biological fluids was assessed. Both urine 
and serum were spiked (as described in sample preparation) using wide concentration range from 
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43.75 ng/µL to 6.25 ng/µL of Des mixed with 25 ng/µL of Labeled-Des standard. The linear 
curves with r
2
 value of 0.997 (Figure 2.3D) and 0.998 (Figure 2.3E) were obtained in urine and 
serum respectively. Results derived from these linearity assays using MALDI-MS
2
 quantification 
methods are consistent for Des, Isodes and their equimolar mixtures in water as well as in spiked 
biological fluids. 
2.4.2.3 Detection Limit 
To determine detection limit of MALDI-MS
2
 quantification method, six successive five-
fold dilutions of Des were spiked into serum and urine. The peak area ratio of Des/Labeled-Des 
in both media remains consistent up to the fifth successive dilution of 0.02 ng/µL (Table 2.1), 
with % RSD less than 5 up to first five dilutions. On the other hand, % RSD observed for the 
next successive dilution increased to more than 8% in serum. Moreover, due to loss in signal  
Table 2.1 Detection limit of MALDI-MS
2
 method- Six successive dilutions of Des in serum and urine 
were evaluated to assess the detection limit of MALDI-MS
2
 quantification method. The consistent result 
in peak area of Des was observed up to fifth successive dilutions with %RSD of less than 5 in both 
biological fluids, serum and urine. 
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intensity at lower concentration of 0.004 ng/µL, peak area ratio of Des/Labeled-Des change 
drastically in urine. This result indicates that MALDI-MS
2
 method can efficiently determine 
concentration as low as 0.02 ng/µL of Des in complex biological matrix such as serum and urine. 
Results from the present study suggest that MALDI-MS
2
 is a sensitive quantification method. 
2.4.2.4 Reproducibility 
To evaluate the reproducibility of the present method, we conducted triplicate studies 
performed by different lab personnel. Response curves for Des in water were generated 
following a similar approach as described in the linearity and dynamic range sections, over the 
time span of two weeks. The run-to-run %RSD values for entire concentration range were less 
than 5% (Figure 2.4) demonstrating the reliability of the current MALDI-MS
2
 method. During  
                 
Figure 2.4 Assessment of reproducibility of MALDI-MS
2
 method- Reproducibility of the present method 
was determined by evaluating the response curve of Des in HPLC water in triplicate by different lab 
personnel. The run-to-run %RSD values for entire concentration range were < 5. 
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the two-week test period, Des, Isodes and Labeled-Des underwent more than three freeze/thaw 
cycles. Thus, these results also demonstrate the stability of Des, Isodes and Labeled-Des 
standards.  
2.4.2.5 UV-irradiation of Des  
Detrimental effects of UV radiation on skin such as loss of elasticity, premature aging 
and wrinkled appearance have been discussed in previous reports [79, 90, 91] which might occur 
as a result of reduction in Des cross-linking of elastin. Moreover, the results of photolysis study 
performed by Baurain et al. showed maximum breakdown of Des and Isodes was observed at 
274 nm and 285 nm respectively [91]. We therefore utilized the current MALDI-MS
2
 method to 
evaluate UV-induced breakdown of Des.  
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Figure 2.5 UV-induced degradation of Des- Degradation of Des was studied by irradiating the sample to 
UV light at 254nm for different time points (0, 5, 15, 30 and 60 minutes). (A) Represents the MS
2
 spectra 
of UV-irradiated Des mixed with 25 ng/µL of Labeled-Des. The fragment ion generated from Des 
(decrease with time) and Labeled-Des are highlighted in orange and blue box respectively. (B) Represents 
the UV-induced breakdown by measuring concentration of Des at different time points using MALDI-
MS
2
 and NMR spectroscopy. 
 
To study the effect of UV radiation on Des degradation, samples were aliquoted and 
analyzed at different time with MALDI-MS
2
 (Figure 2.5A). Additionally, to validate the change 
in concentration observed using our method, we have also quantified Des using NMR 
spectroscopy and compared the results of the two methodologies. The results of MS
2
 analysis 
distinctly demonstrate decrease in relative abundance of Des fragment ion (397 m/z) with time. 
The peak area of 25 ng/µL Labeled-Des fragment ions (m/z= 400 + 401) was used as a reference 
to determine the concentration of Des standard at zero-time point. In the NMR study, a peak in 
the aromatic region (8.42ppm) observed in the non-irradiated control spectrum, as well as the 
spectra of all timepoints, was used to track the UV-induced breakdown Des. The results obtained 
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from MALDI-MS
2
 and 
1
H NMR analysis at different time points are shown in Figure 2.5B. The 
results from both analysis indicate that Des concentration reduces to roughly half after 5 min of 
UV-radiation. Furthermore, an identical pattern of decrease in concentration of Des with 
different time intervals was observed from 
1
H NMR and MALDI-MS
2
 method. The first-order 
rate constants estimated using MALDI-MS
2
 method and NMR spectroscopy are 0.110 ± 0.021 
min
-1
 and 0.124 ± 0.008 min
-1
 respectively. 
2.4.2.6 Comparison to existing methods 
  The current state of the art in detection of desmosines utilizes LC-MS/MS methods 
either with or without stable isotope-labeled standards [86, 92, 93]. The approach presented here 
shows similar performance characteristics, such as precision, accuracy and sensitivity, while 
leveraging the strengths unique to MALDI. For example, current LC-MS run times range from 
12 minutes [93] and longer and require column equilibration between runs.  We typically take a 
conservative approach and interrogate our MALDI spots for 3-5 minutes, but even with 1 minute 
scans, we are able to maintain accuracy and reproducibility (data not shown). Additionally 
MALDI requires no equilibration between samples; the time to move between MALDI spots is 
about 5 seconds. In addition, the MALDI approach reduces the expense and environmental 
impact of solvent usage by multiple orders of magnitude. Each MALDI spot requires 10 
microliters or less of solvent to prepare. 
The MALDI approach also has the benefit that spectra do not need to be extracted from 
an LC run, and detection and quantification of peaks can be fully automated via software. 
Additionally, our MALDI approach consumes only a small fraction of each spot, and therefore 
unlike destructive LC-MS approaches, our samples can be re-analyzed for Des or for other 
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purposes. The tolerance of MALDI towards moderate amounts of contaminants allows fewer 
cleanup steps. For example, no purification is required before the analysis of urine or serum; we 
have used similar MALDI approaches to quantify desmosines directly from hydrolysates of 
elastin without purification [78, 79]. Therefore we believe that our MALDI approach represents 
a robust, novel methodology that can complement existing LC-MS techniques. 
2.4.3 Conclusions 
Although the application of LC-MS/MS methods for determination of Des/ Isodes in 
various body fluids has met a certain amount of success, there is still a need for a simpler, more 
rapid, reliable and sensitive quantification method. MALDI-MS
2
 method offers these traits, 
including excellent sensitivity and shorter analysis time due to elimination of chromatographic 
separation, while maintaining similar analytical characteristics. The present study is the first 
attempt, to our knowledge, to demonstrate and characterize the use of MALDI-ion trap MS
2
 to 
quantify Des/Isodes. We have evaluated concentration ranges from >100 ng/µL down to 0.02 
ng/µL without prior concentration steps like solid-phase extraction, and found the MALDI-MS
2
 
to perform similarly to existing LC-MS/MS methods with the increase in speed and reduction in 
per-run expense associated with chromatography-free MALDI ionization. Our results from the 
evaluation of the linearity and dynamic range, detection limit, and reproducibility successfully 
demonstrate its efficacy of MALDI-MS
2
 method for quantification of biomolecules. The case 
study performed on the quantification of Des breakdown by irradiation of UV light using 
MALDI-MS
2
 explicitly demonstrates consistency between results derived from NMR spectra 
and the current quantification method. Thereby we believe MALDI-MS
2
 has potential to be 
applied in clinical lab setting to diagnose conditions which induce elastin degradation. 
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2.5 Application of MALDI-Ion Trap tandem mass spectrometry based quantification 
method to measure effect of UV-A radiation on the elastin cross links  
While the relationship between UV radiation and photoaging of skin has been 
established, the exact change that elastin undergoes when exposed to UV radiation is still 
unclear. One common belief is that elastic fibers are denatured or cleaved by UV radiation, and 
that most of the elastotic material is produced after exposure to UV radiation or its disorganized 
structure gives aged skin its characteristic wrinkled appearance. In previously reported studies, 
electron microscopy, histology, TEM (transmission electron microscopy), and SEM (scanning 
electron microscopy) have been applied to probe macroscopic changes to the elastic fiber in aged 
and photodamaged skin [94-96]. For all biological damage associated to sun exposure, UV-B 
contributes 80% whereas UV-A contributes only 20% even though approximately 95% of 
terrestrial UV-radiation is UV-A [97]; more work is needed to better understand the microscopic 
changes that UV-A irradiation causes to the structure of elastin. We conducted this in-vitro study 
to uncover changes on elastic fibers that undergo when exposed to high intensity UV-A 
irradiation. Mass spectrometry was also implemented to quantify changes in the relative amount 
of desmosine cross-links. Elastic fibers were then examined histologically and by TEM to 
observe macroscopic changes that resulted from irradiation. 
13
C solid state NMR spectroscopy 
was performed to measure possible structural alterations of elastin. These combined methods 
provide additional information relating to the detrimental effects of UV-A irradiation to the 
structure of the elastic fiber and of elastin. 
2.5.1 Material and Methods 
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2.5.1.1 Sample preparation 
Bovine nuchal ligament elastic fibers purchased from Elastin Products Company, LLC 
(Owensville, MO) were used for this study. These samples were purified by Elastin products 
Company using a known protocol [98] and were free of fat, collagen, smooth muscle cells, and 
other connective tissue. In a prior study, we showed that the protocol used for isolating elastin 
did not alter the structure of the protein, or the concentration of cross-links [99]. Elastic fibers 
were completely immersed in distilled water while being irradiated with a 3U40W UV-A lamp 
(Cnlight Co, China) with a center wavelength of 365 nm which was placed 10 cm above the 
sample. During irradiation, the system was covered with a shield to ensure that the sample was 
isolated from other light and were submerged in water during irradiation. The irradiation 
intensity was 12 mW/cm
2
 and samples were continuously irradiated for 9 days. The intensity of 
the UV-A lamp is therefore approximately 3 times higher than that of the sun, when directly 
overhead (located at the zenith). 
2.5.1.2 Histology and microscopy 
Unirradiated elastic fibers and fibers following 9 days of UV-A irradiation were used for 
the histological study. For histology, a small amount of sample was placed overnight in 100 ml 
phosphate buffered saline. The samples were then placed in Lieca Cryo-Gel (SPI supplies 
Product Ref-02694-AB), sectioned on a Leica CM1850 cryostat at 10 μm, and stained using the 
Sigma-Aldrich elastic stain kit (REF HT25A-1KT) following a modified version of a previously 
reported protocol [100]. The slides were gently rinsed with 95% ethanol, and then placed in 
xylene for a few seconds. Cover slips were then mounted using an Eukitt quick-hardening 
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mounting medium (Sigma-Aldrich REF 03989) and left to dry overnight. All sections were 
photographed using a National Optical DC4-156-S digital microscope at a magnification of 10×.  
2.5.1.3 Transmission Electron Microscopy (TEM) 
Bovine nuchal ligament elastic fibers were immersed in 0.1 M phosphate buffered 
solution (pH-7.4) for 1 h. All the samples were stained with osmium tetroxide and embedded in 
epoxy resin. Samples were sliced along the plane that was perpendicular to the fiber axis, with a 
thickness of 60 nm and examined in a JEM-2000EX transmission electron microscope. The 
accelerating voltage used was 120 kV.  
2.5.1.4 
13
C NMR experimental parameters 
  Prior to the NMR experiments, unirradiated and 9 days UV-A irradiated samples were 
immersed in distilled water and solid-state NMR experiments were carried out on hydrated 
samples. 
13
C NMR experiments were performed using a Bruker Avance (Billerica, MA) 
spectrometer at a magnetic field strength of 21.10 T. All the experiments were carried out using a 
4mm center packing rotor with an insert to keep the samples hydrated, as well as to center the 
samples with respect to the RF coil. 
13
C MAS (magic angle spinning) spectra were measured 
using a DEPTH sequence (to suppress background carbon signals arising from rotor inserts and 
the probe head) [101, 102] with 80 kHz TPPM decoupling [103] at (300±1) K and direct 
polarization. The spinning speed was set to 14.5 kHz for all the samples and spectra were 
acquired by accumulating 18,800 scans. The 
13C π/2 pulse was 54 μs and the recycle delay was 
6s. Analysis of data was performed using MATLAB and matNMR with a Gaussian 
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multiplication broadening factor of 100 Hz. 
13
C NMR spectra were referenced to adamantane 
(TMS=0 ppm). 
2.5.1.5 Sample hydrolysis and quantification with Labeled-Des  
Elastic fiber samples for this study were lyophilized for 24 h prior to hydrolysis. 
Approximately, 2.1–2.2 mg of each sample was placed into a solution containing 300 μl of 6 M 
HCl and 1 μl of 0.5% w/w phenol solution. The sample and solution mixture was placed into a 
vacuum hydrolysis tube, flushed with nitrogen gas, and then evacuated. The samples were kept 
at 110 °C for 96 h, afterward the solvent was frozen in liquid nitrogen and lyophilized for 8–10 
h. After lyophilization, each sample was suspended in a 50 μl solution of 94.5% 0.14 M sodium 
acetate, 0.5% triethylamine, and 5% acetonitrile (v/v/v) at a pH of 7.5. Resuspended samples 
were diluted to 100-fold. Labeled d4-desmosine standard (Toronto Research Chemicals, 
Toronto, Canada) at final concentration of 10 pmol/μl was mixed with the diluted samples in 
three different ratios 1:1, 3:1, and 1:3. The relative amount of desmosine in each sample was 
quantified with respect to mass spectrometric peak area of standard desmosine in MS
2
 mode. For 
statistical analysis of the data, a t-test was used assuming our data followed a normal 
distribution, and using the standard deviations in each sample studied. Null hypothesis 
probability was measured indicating the level of significance of our data. 
2.5.2 Results and Discussion 
UV-A induced alterations of the elastic fiber to follow the effect of UV-A exposure on 
elastic fibers, bovine nuchal ligament fibers with and without UV-A irradiation were 
investigated. Representative histological images of 9 days UV-A irradiated and unirradiated 
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elastic fibers are shown in Figure 2.6. From the figure, it is clear that in an unirradiated sample, 
multiple dense layers of elastic fibers are arranged in a regular fashion; the fibers appear 
relatively straight and are not fragmented. This regular pattern is dramatically disrupted after 
UV-A irradiation by 9 days (Figure 2.6, right panel).  
 
Figure 2.6 Histological images of unirradiated (left) and 9 days irradiated (right) bovine nuchal ligament elastic 
fibers. Images were photographed at 10× magnification and elastic fibers are stained black. The onset of 
fragmentation and disruption in ordering of elastic fibers is evident following UV-A exposure. The scale bar in the 
figures shown is 100 μm. 
 
UV-A exposure results in fragmentation of elastic fibers and alters the regularly ordered 
arrangement of the fibers as well. Moreover, elastic fibers appear thinner compared to that of 
unirradiated samples; the observed alterations in the elastic fibers due to UV-A irradiation 
follows the work previously reported in the literature [95]. It is known that the level of elastase 
increases due to UV irradiation in-vivo which initiates elastin degradation [104, 105]. Imayama 
et al. applied SEM and TEM to study the elastic fibers of dermal connective tissue and showed 
that UV-irradiation alters the elastic fiber by formation of new elastic fibers which later form an 
irregular network [91]. In their study, they irradiated the soles of Sprague-Dawely rats with UV-
B (130 mJ/cm
2
 for 3 min/day up to 12 weeks) and therefore it was possible to follow the 
formation of new elastin. In the present in-vitro study, cells have been removed by the 
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purification step, consequently, elastic fibers are not repaired. Thus, this in-vitro measurement 
allows for characterization of alterations that occur as a result of break down in the cross-links of 
elastin, discussed below, which in turn degrade their structure.  
TEM was used to follow the macroscopic alterations of UV-A exposure on elastic fibers. 
Figure 2.7 shows TEM images of the sample without UV-A exposure and with 9 days of UV-A 
exposure. In the images, the elastic fibers are in white denoted ‘a′, the interstitial spaced between 
fibers is denoted ‘c′ and cracks within or on an edge of fibers denoted ‘b′. Due to UV-A 
irradiation, pronounced cracks are observed in the 9 days irradiated sample, both in the interior 
of the elastic fiber and on the edges. Similar to the histological measurements, elastic fibers 
appear sparser and thinner in the 9 days irradiated sample, compared to the unirradiated sample.  
            
Figure 2.7 TEM images of (left) unirradiated and (right) 9 days irradiated elastin samples taken cross-sectionally 
(fiber axis points into the page). In the images, the light gray color (a) denotes an elastic fiber, (b) cracks on the edge 
or within the elastic fiber are as a result of UV-A exposure, and (c) the interstitial space between fibers. 
 
UV-A exposure may initiate microscopic changes of the structure or dynamics of the 
principal protein, elastin, in the elastic fiber. To follow these changes, 
13
C MAS NMR 
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experiments were carried out. Chemical shift assignments of all major amino acids (e.g. glycine, 
proline, valine) that comprise the spectra shown in Figure 2.8 were made following previously 
reported measurements of elastin and its related peptides [99, 106-110]. A detailed discussion of 
the peak assignments and structures observable in elastin has been reported elsewhere [99, 111].  
 
Figure 2.8 
13
C MAS NMR spectra of aliphatic region of unirradiated (top) and 9 days UV-A irradiated (bottom) 
elastic fibers recorded at 300 K. Peak assignments were made using values published in the literature, as discussed 
in the text. The spectra were acquired by accumulating 18,800 scans at 14.5 kHz magic angle spinning speed at a 
magnetic field strength of 21.10 T. 
 
Experimental studies of the structure of elastin by modern NMR methodology are 
difficult due to the large, highly cross-linked nature of the protein. Even with isotopic labeling, 
degeneracies present in the spectra make structural elucidation challenging—in the present work 
we apply magnetic resonance spectroscopy to reveal secondary structural changes or dynamics 
due to UV-A exposure. All 
13
C peaks in these samples (unirradiated and 9 days irradiated) 
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appear in the same position and no significant chemical shift differences were observed. These 
measurements reveal that any microstructural changes of elastin following 12 mW/cm
2
 of UV-A 
irradiation for 9 days do not appear to alter the 
13
C NMR chemical shifts of the most abundant 
amino acids that comprise the protein. 
2.5.2.1 Biochemical changes of elastin due to UV-A exposure 
The detrimental effects of UV rays on the cell and extracellular components (e.g., elastin, 
collagen, etc.) of skin are already known to some extent [94, 95, 97, 104, 112, 113]. Sun exposed 
skin showed abnormalities which include fiber disintegration, thickening, and proliferation of the 
elastic fiber [94]. A marked decrease in the linearity of the elastic fiber is also observed due to 
UV exposure [95]. Chatterjee et al. observed skin wrinkling when hairless mice were exposed to 
UV-B irradiation and followed different biochemical parameters. Biochemical parameters such 
as water, elastin, and glycosaminoglycan content were observed to increase whereas the collagen 
content remained the same after UV-B irradiation [104]. However, a different study showed that 
both UV-A and UV-B irradiation increase the concentration of elastin while the collagen content 
remains unaffected [113]. To obtain qualitative assessment of the macroscopic damage in elastic 
fiber that occurs in 9 days of UV-A exposure and to relate these changes to the actinic damage, 
we compare the UV-A irradiation from the lamp used in this study with that of the sun over the 
same period of time. Taking the total intensity of light on earth surface (1400 W/m
2
) one finds 
that the energy deposition from the UV-A lamp was 2.85 times higher compared to that of 
continuous exposure to the sun for duration of 9 days. For this calculation we assumed that only 
3 % of the incident solar energy is UV radiation, and that the sun is at the zenith [114]. This 
computation does not account for any attenuation of the UV radiation, e.g. through the dermis, 
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which may act as a layer of protection to the elastic fibers and reduce the intensity of the incident 
radiation. Des and Isodes form the cross-linking domains of elastin and their relative 
concentrations may be used as a measure of biochemical changes. The effects of UV radiation on 
isolated Des and Isodes have been reported previously by Baurain and coworkers [115]. Their 
study showed photolytic reaction results free lysine due to breaking down of pyridinium rings of 
Des/Isodes. However, the production of lysine depends on several factors such as irradiating 
wavelength, pH, and irradiation time. The formation of lysine was 35% when they irradiated Des 
at 274 nm for 25 min, whereas, for Isodes the irradiation dose was 285 nm for 50 min and yield 
was 78%. At wavelengths of 320–400 nm (UV-A), the absorbance in desmosine is ≤0.05 [115].  
In the present study, we quantify the reduction of desmosine due to UV-A in bovine 
nuchal ligament elastic fibers by MS
2
 experiments. In these measurements, the unirradiated 
sample was used as a control. The relative amount of desmosine in the 9 days UV-A irradiated 
sample was normalized with the amount of Des in the unirradiated sample. The results indicate 
the amount of Des in sample without UV radiation was 1.00 ± 0.01 mg, while amount of Des 
observed after 9-days of UV radiation was 0.89 ± 0.04 mg. The result showed the relative 
amount of Des in the 9-days irradiated sample was found to decrease by approximately 11%. The 
decrease in the relative content of Des arises from the breakdown of cross-links as a result of the 
irradiation, as each measurement was made per unit mass of the lyophilized sample prior to 
hydrolysis. 
A previous in-vivo study on hairless mice skin showed that the desmosine content 
increases when treated with UV-A or UV-B [104, 113]. Chatterjee et al. observed an increase in 
elastin content per unit area of mice skin with UV-B exposure (40 mJ/cm
2
) of 18 weeks 
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irradiating three times a week [104]. However, Johnston et al. did not observe any statistically 
significant difference in the relative desmosine content when purified elastin was treated using 1 
and 10 J of UV-A [113]. In the current in-vitro study, an 11% decrease in desmosine content is 
observed in 9 consecutive days of UV-A irradiation using approximately 42 kJ, whereas in the 
previous work by Johnson et al., 1 J for 6.25 min was employed [113]. Previous studies suggest 
that UV-B is more detrimental to the asthetic and mechanical functionality of skin than UV-A. 
However, the results obtained in the present study show that UV-A may play a greater role in 
photoaging of skin than previously believed. Thus, the findings of this work indicate that cross-
linking of tropoelastin is measurably reduced following UV-A irradiation and this breakdown 
may alter its biomechanical characteristics during prolonged exposure if not repaired. Chung and 
coworkers [114] have observed a marked increase in MMP-12 activity following UV exposure, 
which causes degradation of the extracellular matrix, including elastin and collagen. The 
reduction of Des following UV-A exposure revealed in this in-vitro study of elastic fibers 
indicates that additional alterations are present before MMP-12 is expressed and other biological 
processes are initiated.  
2.5.3 Summary and future directions 
 The current study introduces a novel approach to quantify Des and Isodes using Matrix-
Assisted Laser Desorption Ionization (MALDI)-tandem mass spectrometry (MS
2
) in a linear ion 
trap coupled to a vacuum MALDI source. MALDI-MS
2
 analysis of Des and Isodes are 
performed using stable-isotope labeled desmosine (Labeled-Des) as an internal standard in 
different biological fluids such as urine and calf serum. The method demonstrated good linearity 
over two orders of magnitude with dynamic range from 3.125 to 125 ng/µL for both Des and 
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Isodes. Detection limit of current quantification method using Des standard is 0.02 ng/µL in 
urine and in calf serum. The method reproducibility (%RSD) is < 5% for Des.  
The method is used to evaluate the time-dependent degradation of Des upon UV radiation 
(254nm) and found to be consistent with quantification by NMR.  This is the first reported 
MALDI-MS
2
 method for quantification of Des and Isodes, and illustrates the potential of 
MALDI-ion trap MS
2
 for effective quantification of biomolecules. The reported method 
represents improvement over current liquid chromatography-based methods with respect to 
analysis time and solvent consumption, while maintaining similar analytical characteristics. 
In future project, we plan to incorporate the solid-phase extraction step prior to MS 
analysis to be able to analyze the extremely low-level of Des in body fluid such as sputum. We 
also aim to implement this MALDI-MS
2
 based quantification method to study the effect of parity 
on the architecture of vaginal elastic fibers in female Sprague-Dawley rats. The female 
reproductive tract is rich in elastic fibers. Elastin, a major component of elastic fibers provides 
elasticity and resiliency to connective tissue of skin, lungs, aorta, and pelvic floor. Many 
physiological conditions such as aging, normal vaginal birth and multiparity can lead to 
weakening of the connective tissue of pelvic floor. Consequently, failure to maintain elastic fiber 
homeostasis after parturition can lead to pelvic floor disorder. Hence, in our collaborative efforts 
with our collaborator Dr. Boutis, we seek change in Des content of vaginal elastic fibers of virgin 
and pregnant (1, 3 and more than 5 birth) rat using this developed quantification approach. 
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3.1 Protein phosphorylation 
One of the most intriguing and challenging areas in the current research is to understand 
cellular mechanism and signaling network integration. An important step to understand these 
cellular processes is to identify and characterize phosphorylation sites in both, individual 
proteins as well as human proteome. Protein phosphorylation is one of the most prevalent post-
translational modifications which play a pivotal role in many cellular processes such as cell 
proliferation, differentiation and migration. Protein phosphorylation involves catalytic addition 
of phosphate group from adenosine triphosphate (ATP) on serine/threonine/tyrosine residues of a 
protein [116].  
Protein phosphorylation is controlled by a wide variety of kinases and phosphatases, 
which themselves may be regulated by phosphorylation. Once a protein is phosphorylated by a 
kinase, the phosphorylation event can cause conformational and functional changes in the protein 
to either turn-on or turn-off the protein – an effective way to regulate protein functions [117]. It 
is estimated that about 30 percent of proteins exist in phosphorylated form at any given time in a 
cell, which indicates that the phosphoproteome has vast and vital role to play in regulating 
various cellular processes [118]. However, less than 10 percent of total potential phosphorylation 
sites have been identified and well-characterized so far [119]. This suggests that even though 
protein phosphorylation is playing vital role to regulate various cellular processes and has been 
investigated for long enough time, tremendous amount of work is still needed to be done. 
3.2 HIV Introduction: 
Human Immunodeficiency Virus (HIV-1) is a causative agent of AIDS. HIV-1 
specifically target host defense cells, notably CD4+T cells, and progressively destroys the ability 
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of the host to fight HIV infection and make the host prone to other diseases. The HIV-1 virus 
uses various host factors for its replication therefore; the infectivity of HIV-1 virus greatly 
depends on the interactions of viral components with various host factors [118, 119]. So, in this 
report we sought to identify and characterize interactions between host-kinases and HIV-protein 
phosphorylation sites that might provide insight into possible regulatory mechanism of HIV-
proteins. Consequently, this investigation might provide a new pathway for development of anti-
HIV therapeutic agents. 
3.2.1 HIV genome 
The HIV-1 genome encodes total of nine open reading frames. Three of these genes 
encode the major structural proteins for virus particle such as Gag, Pol, and Env polyproteins. 
These polyproteins further proteolyzed into individual proteins. The Gag polyprotein proteolyzed 
into four different proteins: Matrix (MA), Capsid (CA), Nucleocapsid (NC) and P6. These 
proteins from gag gene provide basic infrastructure for the virus particle. The Env polyprotein 
cleaved into two Env proteins gp120 (SU- surface) and gp41 (TM- transmembrane). Together 
with Gag proteins, Env proteins are also a part of structural components that make up the core of 
the virion and outer membrane envelope [119]. The three Pol proteins known as Protease (PR), 
Reverse Transcriptase (RT), and Integrase (IN), perform essential enzymatic functions, and are 
involved in viral replication [120]. In addition to these structural proteins, the HIV-1 virus 
particle also encodes six additional proteins, which are called auxiliary proteins. Three of these 
proteins, such as Virus infectivity factor (Vif), Viral protein R (Vpr), and Negative regulator 
factor (Nef) are found in the viral particle known as accessory regulatory proteins. The other 
two, essential regulatory proteins known as Transactivator of transcription (Tat) and Regulator of 
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expression of the virion (Rev), provide essential gene regulatory functions. Finally, Vpu 
indirectly assists in assembly of the virion by enhancing the release of the progeny virion and 
inducing degradation of the CD4 receptor [121]. These auxiliary HIV proteins play important 
roles in host-pathogen interactions and have significant impact on course of HIV infection. The 
retroviral genome also contains two copies of single-stranded RNA molecules. So, in simplistic 
terms, HIV-1 may be considered as a molecular entity consists of 15 proteins and RNA. 
Figure 3.1 Structure of genome organization of HIV-1 particle [121] 
3.2.2 Essential roles of HIV proteins 
There are 15 different HIV-1 proteins, distinctly categorized into three different classes 
based on their functions: 1) structural proteins, 2) regulatory proteins, and 3) accessory proteins. 
Table 3.1 shows the list of HIV-1 proteins and their essential functions. 
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Table 3.1 List of HIV-1 proteins and their primary functions 
HIV protein Protein function 
    
Matrix, MA (p17gag) Target Gag to plasma membrane binding for virion assembly 
  Facilitate the nuclear transport of viral genome 
    
Capsid, CA (p24gag) Formation of virion core structure and assembly 
    
Nucleocapsid, NC (p7gag) Virion packaging of genome RNA 
  Act as a RNA chaperone 
  Facilitate reverse transcription 
    
p6gag Promote efficient release of budding virions  
    
Protease, PR Proteolytic processing of Gag and Gag-Pol polyproteins 
    
Reverse Transcriptase, RT Synthesis of viral DNA from viral RNA 
    
Integrase, IN Covalent insertion of viral proviral DNA into cellular DNA 
    
Surface Glycoprotein, Bind to cell-surface receptors 
SU (gp120env) Mediate virus attachment and entry 
    
Transmembrane Glycoprotein Mediate membrane fusion and virus entry 
TM (gp41env) 
    
Virion Infectivity Factor, Vif Suppress APOBEC3G/3F (host factors that inhibit infection) 
    
Viral Protein R, Vpr Facilitate nuclear localization of preintegration complex (PIC) 
  G2/M cell-cycle arrest 
    
trans-Activator of Transcription, Activate viral transcription through interaction with TAR 
Tat   
    
Regulator of Expression of  Induces nuclear export of intron-containing viral RNAs 
Virion Protein, Rev Essential post-transcriptional regulator of virion gene 
expression 
    
Viral Protein U, Vpu Degradation of cellular receptor CD4 
  Induces virion release from host cell surface 
    
Negative Regulator Factor,  Downregulation of cell expression of CD4 
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Nef T-cell activation 
  Moderate enhancer of viral infectivity 
  Downregulation of Class I MHC 
 
3.2.3 Known phosphorylation events of HIV proteins 
Many reports have been published to date demonstrating that phosphorylation events 
regulate the functions of various viral proteins and play a vital role in HIV infection. Hence, 
strategies that can reverse or inhibit the phosphorylation events have also been proposed as one 
of the possible mechanisms to halt or slow down the HIV infections in many instances. Some 
examples of phosphorylation events in HIV proteins are: Vif [122-124], Rev [125-127], Vpr 
[128, 129], Vpu [130, 131], Nef [132-134], Tat [135-137], P6 [138], Integrase (IN) [139], Capsid 
(CA) [140], Matrix (MA) [141-144], and Reverse Transcriptase (RT) [145]. These 
phosphorylation events in different HIV proteins play many vital roles including viral entry to 
host-immune cell, viral replication, and budding. Some examples are described below: 
1. Phosphorylation of Tyrosine residue in Matrix (MA) protein leads to its association with 
viral Integrase (IN) enzyme in the nucleoprotein complex and aids targeting of Pre-
integration complex (PIC) to the nucleus [146, 147]. 
2. Phosphorylation of Reverse Transcriptase (RT) at Thr216 by host CDK2, increases in-
vitro and in-vivo RT activity and viral infectivity [145]. 
3. Phosphorylation of Tat by RNA dependent cellular protein kinase (PKR) enhances the 
binding to TAR RNA [136]. Moreover, phosphorylation of Tat by PKR also assists in 
evasion of host anti-viral mechanism. 
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4. Vpr is known to be phosphorylated at three sites including Ser79, Ser94 and Ser96. Zhou 
et al. study shows that phosphorylation of Ser79 is required for cell cycle arrest, while 
mutation of all three sites attenuated HIV-1 replication in macrophage [128]. 
5. The 23 kDa Vif protein is phosphorylated at five sites including four sites in the C-
terminal region. The substitution of phosphorylatable residues, Thr96 and Ser144 results 
in loss of 90% of Vif activity and inhibits HIV-1 replication [123, 124]. 
6. Phosphorylation of Vpr by protein kinase A (PKA) at Ser79 activates Vpr-induced cell 
cycle arrest during HIV-1 infection [129]. 
7. Phosphorylation of N-terminal Nef residues by serine kinases influences the viral 
infectivity [148], while phosphorylation of Nef by protein kinase C (PKC) enhances 
CD4-down regulation [149]. Furthermore, phosphorylation of Ser6 in Nef modulates HIV 
transcription, replication rates and subcellular localization [132]. 
8. Integrase is modified by JNK phosphorylation followed by Pin1-catalyzed prolyl cis/trans 
isomerization, steps necessary for genomic integration in CD4+ T cells [139]. 
3.2.4 Experimental Workflow 
Preliminary goal of the current investigation is to identify one or more phosphorylation 
sites across various HIV proteins and study the influence of identified phosphorylation event on 
HIV infection. This investigation may successfully introduce a definitive database of host-cell 
kinase/HIV phosphorylation substrate interactions, which may prove as a strong pillar for further 
investigation of anti-HIV therapeutics. Following are the strategic steps adopted to achieve this 
aim: 
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Step-1: Multiple sequence alignments of individual HIV-protein:  
We have constructed multiple sequence alignments using 12 different strains of HIV to 
identify conservation in phosphorylation sites across each HIV protein using ClustalW software. 
The conservation of phosphorylation sites in a protein reflects their possible biological 
importance in function of HIV-1 protein. In our study, we focus specifically on the Serine (Ser), 
Threonine (Thr) and Tyrosine (Tyr) residues that demonstrate low entropy and conservation 
across different strains. 
Step-2: Kinase-specific phosphorylation site prediction algorithms: 
HIV protein sequences have been evaluated by web-based kinase-specific 
phosphorylation site prediction algorithms such as NetPhosK, GPS (Group-based prediction 
system) and KinasePhos. These algorithms not only provide prediction of potential 
phosphorylation sites in HIV proteins but also identify the host-kinase with prediction scores for 
each possible phosphorylation site.  
Step-3: In-vitro kinase assay of HIV-peptides and proteins: 
Libraries of short synthetic peptides derived from HIV proteins sequence containing 
candidate phosphorylation sites (identified from step 1 and 2) are subjected to in-vitro kinase 
assay with respective kinases in presence of ATP. Kinase activity is assayed using MALDI-ion 
trap mass spectrometer, which has the benefits of less sample requirements, rapid readout, and 
MS
n
 capabilities for structural elucidation. Preliminary hits from this initial screening are then be 
evaluated on protein level. In future, biochemical effects of phosphorylation will be investigated 
by assessing the differences in activity as well as stability of different HIV proteins as a function 
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of phosphorylation state. This study will confirm biological relevance of in-vitro phosphorylation 
sites, and generate hypotheses for future studies focusing on mechanistic characterization of 
discovered HIV phosphorylation sites. 
3.3 Materials and Methods 
Various kinases such as Glycogen Synthase Kinase 3 (GSK-3), p42 MAP kinase, cAMP-
dependent Protein Kinase (PKA), Casein Kinase I (CKI), Casein Kinase II (CKII), 
CDK2/CyclinA, CDK2/CyclinE, CDK4/CyclinD, CDK9/CyclinT1, CDK7/CyclinH, 
CDK1/CyclinB and 1x NEBuffer (50mM NaCl, 10mM Tris-HCl, 10mM MgCl2, and 1mM DTT) 
were purchased from New England BioLabs (MA, USA). Other kinases such as CDK5/p25, 
CDK5/p35, p38 MAPK and Protein Kinase C- [alpha, beta (II), theta, and delta] were purchased 
from Enzo Life Science (NY, USA). The protease for in-gel protein digestion including trypsin, 
chymotrypsin, and Arg-C were purchased from Promega (Madison, WI, USA) and Glu-C was 
purchased from Thermo Fisher Scientific (Waltham, MA, USA). The library of small synthetic 
HIV-derived peptides together with different full-length HIV-proteins was ordered from National 
Institutes of Health AIDS Research & Reference Reagent Program. 
3.3.1 In-vitro kinase assay of HIV-peptides/proteins 
10μM HIV-peptide/protein of interest was incubated with 1μM kinase in presence of 
4mM ATP and 1X NEBuffer at 30˚ C. Sample was aliquoted at different time interval- 30 min, 1 
hour, 3 hours and overnight. 1μL of sample was deposited on MALDI sample probe after 
addition of CHCA (alpha-cyano-4-hydroxycinnamic acid) matrix solution in ratio of 1:14(v/v). 
Thermo Scientific MALDI LTQ-ion trap mass spectrometer was employed for mass 
spectrometric analysis. 
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3.3.2 In-gel protein digestion 
After incubation of lead kinase (identified from in-vitro kinase study of HIV peptides) 
with HIV protein (Vif, Nef or P24) for 4 hours, samples were separated by NuPAGE gel and 
stained using GelCodeTM Blue Safe Protein Stain (Thermo Scientific). The protein bands were 
cut out followed by digestion with proteases (trypsin, chymotrypsin, Arg-C and Glu-C) at 37 °C 
for 4 hr. The protease was added to a final substrate-to-enzyme ratio from 100:1 to 20:1 and 
optimum pH was maintained (according to standard in-gel digestion protocol provided by 
vendor). Following the in-gel digestion of protein, peptide extraction was performed using 
POROS 20 R2 resin (Applied Biosystems) for 4hr at 4°C. The ZipTip (Millipore) was employed 
to desalt the peptide fragments prior to MALDI mass spectrometric analysis. The sample eluted 
from ZipTip using CHCA matrix solution was directly delivered onto a MALDI sample probe, 
and analyzed using MS and MS
2
 modes. Identification of peptide mass, phosphopeptide peaks 
and interpretation of MS
2
 and MS
3
 spectra was performed manually using ProteinInfo 
(Rockefeller University, NY; http://prowl.rockefeller.edu).  
3.4 Results and Discussion 
The first collaborative project between our lab and Massachusetts General Hospital (Dr. 
Mathias Lichterfeld) revealed that effective HIV-1 reverse transcription depends on 
phosphorylation of viral reverse transcriptase (RT) by host cyclin-dependent kinase CDK2 at 
highly conserved amino acid residue (Thr216) [145]. They investigated functional relevance of 
CDK2- dependent phosphorylation of HIV-1 RT by substituting Thr216 with Alanine (Ala) and 
observed that replacement of Thr216 residue results in absence of phosphorylation and reduction 
in viral infectivity. CDK-2 dependent phosphorylation increased efficacy and stability of viral 
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reverse transcriptase (RT), an enzyme which is responsible for synthesis of viral DNA from viral 
RNA, a critical step in HIV infection. Consequently, we decided to further study and 
characterize potential phosphorylation sites across various HIV-1 proteins to evaluate the effect 
of HIV-1 protein phosphorylation on the course of HIV infection. This study was conducted 
mainly in three phases: 1) Investigation of potential CDK-mediated phosphorylation sites of HIV 
proteins, 2) Investigation of potential phosphorylation sites in HIV auxiliary proteins, and 3) 
Investigation of potential phosphorylation sites in HIV structural proteins. 
3.4.1. Investigation of potential CDK-mediated phosphorylation sites of HIV proteins 
The investigation to evaluate potential CDK-mediated phosphorylation sites across 
various HIV-1 proteins was initiated with a set of 22 potential phosphorylation sites containing 
HIV-peptides. These HIV-peptides were selected based on the presence of minimal CDK-
mediated phosphorylation motif, (S/T)PX, where X represents any amino acid, and (S/T)P means 
Serine or Threonine residue followed by Proline. Six different cyclin-dependent kinases (CDK)s 
including CDK2/Cyclin A, CDK2/Cyclin E, CDK4/Cyclin D, CDK9/CyclinT1, CDK7/CyclinH, 
CDK1/CyclinB were chosen to perform in-vitro kinase assays on these HIV-peptides.  
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Table 3.2 List of 22 HIV-peptides containing CDK-mediated phosphorylation motif, (S/T)PX are shown 
below. The last column represents mass of the peptides. 
 
The result of the in-vitro kinase assays indicates that 8 out of 22 potential 
phosphorylation sites have shown to be phosphorylated in presence of different CDKs. For 
example, when the peptide derived from VIF protein (VIF-B-21) having sequence of 
(AALITPKKIKPPLPSVTK) was incubated with CDK2/Cyclin E and ATP, for 1hr, 3hr and 
overnight, a time-dependent increase in phosphopeptide peak was observe in mass spectrometric 
analysis (Figure 3.2). The presence of a robust, CDK dependent peak at 1982.82Da with mass 
difference of +80Da, represent addition of phosphate group (HPO3) to the control VIF-B-21 
peptide peak (1902.73Da). To verify the presence of the mass peak at 1982.82Da was due to 
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Figure 3.2 In-vitro kinase assay result of VIF-B-21 peptide- Mass spectra of VIF-B-21 peptide 
(AALITPKKIKPPLPSVTK- 1902.73Da) in presence of CDK2/Cyclin E and ATP at different time points 
(0hr, 1hr, 3hr, and overnight) are shown here. Time-dependent increase in the mass peak at 1982.82Da 
shows the CDK-dependent phosphorylation of VIF-B-21 peptides. 
 
CDK-mediated phosphorylation of VIF-B-21 peptide, phosphopeptide (1982.82Da) was 
subjected to MS/MS analysis. In principle, collision induced dissociation (CID) generate a strong 
signal at -98Da from the phosphorylated mass peak that correspond to the neutral loss of 
phosphoric acid (H3PO4). The presence of this ion in the MS
2 
spectra (Figure 3.3) is considered 
as conclusive evidence of phosphorylated peptide ions. Furthermore, other fragment ions 
generated from the peptide backbone were also investigated to find out correct phosphorylation 
site. Fragment ions such as b10, b*13 and b*14 (representing N-terminal peptide fragments) that 
contain phosphorylated-(Thr5), represent the mass of the fragment ions with attachment of 
phosphate group, while other fragment ions, y”11 and y”13 (representing C-terminal peptide 
fragment), which does not contain phosphorylated-(Thr5) residue represent the original mass of 
fragment ions. Thus, this investigation confirms the phosphorylation of (Thr5) of VIF-B-21 
peptide in presence of CDK2/Cyclin E and ATP. The summary of in-vitro kinase assays 
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performed on the CDK consensus motif containing HIV-peptides are shown in Table 3.3. The 
list represents only those HIV-peptides that showed the presence of phosphorylation upon 
incubation with CDKs in presence of ATP.  
Figure 3.3 MS
2
 spectrum of the phosphorylated VIF-B-21 peptide: MS
2
 fragmentation indicates the 
presence of a strong peak with difference of 98Da from the parent mass peak correspond to neutral loss of 
phosphoric acid. The analysis of various backbone fragmentation of phosphorylate VIF-B-21 peptide 
suggest the attachment of phosphate group on (Thr5) of the VIF-B-21 peptides. 
 
Table 3.3 represent list of HIV-derived peptides show phosphorylation using different CDKs. (+++, 
phosphorylated peak is at least equally as intense as unphosphorylated; ++, 25-100%; + 2-25%; - <2%) 
 
 
Beside the investigation of the aforementioned 8 HIV-peptides in presence of various 
CDKs, the in-vitro kinase study was also conducted on these HIV-peptides with few other 
kinases such as, casein kinase I (CK1), Casein kinase II (CKII), mitogen-activated protein kinase 
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(MAPK), glycogen synthase 3 (GSK-3), protein kinase B (PKB), and different isozymes of 
protein kinase C (PKC-alpha, beta, delta). These kinases were selected based on their high 
phosphorylation prediction scores obtained from phosphorylation prediction algorithms. 
Table 3.4 Results of in-vitro kinase assay for CDK consensus motif containing 8 HIV-peptides- In-vitro 
kinase assays performed on 8 HIV-peptides in presence of specific kinases with high prediction score 
obtained using various phosphorylation prediction algorithms such as NetPhosK, GPS and KinasePhos. 
(+++, phosphorylated peak is at least equally as intense as unphosphorylated; ++, 25-100%; + 2-25%; ---, 
no phosphorylation) 
 
3.4.2 Investigation of potential phosphorylation sites in HIV-1 auxiliary proteins 
HIV-1 auxiliary proteins play vital role in HIV replication and infection. Moreover, many 
publications have been shown the importance of phosphorylation events of these auxiliary 
proteins in HIV infection [124, 127, 129, 130, and 132]. There are six HIV-1 auxiliary proteins 
in HIV viral particle such as Nef, Rev, Tat, Vif, Vpr and Vpu. For all these HIV auxiliary 
proteins multiple sequence alignment using ClustalW was performed to evaluate the 
conservation of serine/threonine/tyrosine across 14 different strains of HIV-1 (Figure 3.4 top 
panel- shows ClustalW result of VIF protein sequence). Furthermore, three different 
phosphorylation prediction algorithms such as NetPhosK, KinasePhos and GPS were employed 
to identify kinase-specific, potential phosphorylation sites across the HIV-1 protein sequence 
(Figure 3.4 bottom panel- shows prediction score of VIF obtained using NetPhosK) 
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U455 MAL HXB2 BRULAI BH10 RF/HAT3 ARVS/SF2 MN ETH2220 92BR02596 NDK ELI Z2/CDC-Z34 Z6
Site Kinase
PKB 0.76 0.76 0.76 0.76 0.76 0.76 0.74 0.73 0.79 0.76 0.76
PKC 0 0.72 0.72 0.72 0.72 0.72 0.72 0.68 0.77 0.72 0.72
PKG 0.53 0.51 0.51 0.51 0.51 0.51 0.51 0 0 0.51 0.51
RSK 0 0 0 0 0 0 0 0 0.51 0 0
DNAPK 0.55 0.52 0 0 0 0 0 0 0.55 0.55 0 0 0 0
PKC 0.69 0.75 0.78 0.78 0.78 0.78 0.78 0.78 0.69 0.69 0.63 0.75 0.78 0.78
cdc2 0 0.51 0 0 0 0 0 0 0 0 0 0.50 0 0
Y-30 INSR 0 0 0 0 0 0.51 0 0 M 0 0 0 0 0
S-32 PKC 0.92 0.93 0.92 0.92 0.92 0.91 0.93 0.93 0.84 0.90 0.92 0.92 0.91 0.91
RSK 0.54 0 0
PKA 0.86 0.63 0.63
PKG 0.51 0 0
Y-40 EGFR 0 0.51 0 0 0 0 0 0 0 0 0 0 0 0
PKC 0.6 0.62 0 0 0 0.53 0.6 0.53 0.55 0 0 0
GSK3 0.52 0.52 0.52 0.52 0.52 0.52
cdk5 0.56 0.56 0.56
PKG 0 0 0 0.51 0.51 0.52
T-47 PKC M M M M M 0.81 0.79 0.81 M M M M M M
S-49 cdc2 0.55 M M M M M M M M M M M M M
PKC 0.59 0 0 0 0 0 0 0
PKG 0 0.51 0.51 0.51 0.51 0.57 0.57 0.57
S-53 RSK 0.58 0 0.54 0.54 0.54 0.54 0.54 0.54 0 0 0 0 0 0
S-23
S-52
S-46
M M
T-20
S-36 M M M M M M
Subtype BSubtype A Subtype C Subtype D
SCORE
00 0
M M M
0 0
0 0 0
00
0 0
0 0
0 0 0 0 0 0
 
Figure 3.4 Vif multiple sequence alignment and bioinformatics prediction score: Top panel represent 
Virion infectivity factor (Vif), protein sequence from different strain is aligned together using ClustalW 
software identifies well-conserve phosphorylation motif in Vif protein across different strains. The 
residues which can be phosphorylate, such as Serine (S), Threonine (T) and Tyrosine (Y) are highlighted 
in purple, blue and green color respectively. Bottom panel represent scoring matrix of NetPhosK 
prediction scores of VIF from each strain. Notation ‘M’ represents mutation at the respected position in 
particular sequence. High prediction score represents high phosphorylation probability. 
 
Based on conservation of the residues (serine/threonine/tyrosine) across various strains 
and high prediction scores obtained from different kinase-specific phosphorylation prediction 
tools, more than ten well-conserved potential phosphorylation sites were identified from three 
HIV auxiliary proteins (Vif, Vpr, and Vpu). Indeed, seven different peptides containing these ten 
potential phosphorylation sites were carefully chosen to perform in-vitro kinase study. 
Simultaneously, more than 8 well-conserved potential phosphorylation sites containing peptides 
from each HIV auxiliary proteins (Nef, Rev, and Tat) were identified and investigated. The 
results of the in-vitro kinase study on these peptides are summarized in Table 3.5 below.  
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Table 3.5 Results of in-vitro kinase assay of peptides from HIV auxiliary proteins- In-vitro kinase assay 
performed using potential phosphorylation site containing peptides from HIV auxiliary proteins in 
presence of potential kinases predicted using bioinformatics tools such as NetPhosK, GPS and 
KinasePhos. (+++, phosphorylated peak is at least equally as intense as unphosphorylated; ++, 25-100%; 
+ 2-25%; ---, no phosphorylation)  
 
Vif, Vpr, Vpu-peptides  MW (Da) CK I CK II PKB PKC PKA GSK3 MAPK 
         
RIRERAEDSGNESEG         1703.78 ++ + 
  
++ 
 
-- 
SLGQHIYETYGDTWA         1739.78 
  
-- + 
 
-- 
 
VDRMRIRTWKSLVKH         1924.09 
  
+ +++ 
  
+ 
VKHHMYISGKAKGWF        1787.93 
   
++ 
  
-- 
RHHYESTHPRISSEV            1833.89 + 
 
-- ++ + + + 
VSIEWRKKRYSTQVD           1894.01 
  
-- ++ 
   
DCFSESAIRNAILGH             1631.77 
   
-- 
   
         
Rev peptides 
        
MAGRSGDSDEELLKT 1607.75 -- +++ -- 
 
-- 
  
DEELLKTVRLIKFLY 1879.08 -- 
  
-- 
  
-- 
RLIKFLYQSNPPPSP 1755.97 
   
-- 
   
WRERQRQIRSISGWI 1970.07 + -- 
  
+++ 
 
+ 
GWILSTYLGRPAEPV 1657.88 
       
CNEDCGTSGTQGVGS 1413.51 -- 
  
-- 
  
-- 
CGTSGTQGVGSPQIL 1403.67  -- 
    
-- -- 
GTQGVGSPQILVESP 1467.76 -- 
  
-- 
  
-- 
VGSPQILVESPAVLE 1536.84 -- 
  
-- 
 
-- -- 
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ESPAVLESGTKEE 1374.65 -- 
  
-- 
 
-- -- 
PSPEGTRQARRNRRR 1836 -- 
    
-- 
 
LQLPPLERLTLDCNE 1752.91 
    
-- 
  
         
Tat peptides 
        
DPRLEPWKHPGSQPK 1770.92 -- 
  
-- 
  
-- 
QPKTACTNCYCKKCC 1692.69 
      
-- 
KGLGISYGRKKRRQR 1802.09 
   
+ 
   
RQRRRAPQDSQTHQV 1861.97  
   
+ 
  
+ 
DSQTHQVSLSKQPAS 1611.79  -- 
     
-- 
HQVSLSKQPASQPRG 1618.85 -- 
  
-- 
   
LSKQPASQPRGDPTG 1537.78 -- 
 
-- 
    
PASQPRGDPTGPKES 1522.74 
       
         
Nef peptides 
        
MGGKWSKRSVVGWPT  1674.87  
  
-- +++ +++ 
 
+ 
SVVGWPTVRERMRRA 1798.97 
   
+++ 
  
+ 
PAADGVGAVSRDLEK  1483.76 
  
-- 
    
LEKHGAITSSNTAAN 1512.75 
       
GAITSSNTAANNADC 1408.59  
      
-- 
QVPLRPMTYKAAVDL  1700.93  
   
+ 
   
YKAAVDLSHFLKEKG 1704.92 
       
ILDLWVYHTQGYFPD 1865.9 
   
-- 
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FPDWQNYTPGPGIRY 1809.85 
      
++ 
VEEANEGENNSLLHP 1650.75 ++ 
 
-- 
    
LHPMSLHGMDDPERE 1762.78 + 
      
LEWKFDSRLAFHHMA 1886.92 
  
-- -- 
   
EKGGLEGLIYSQKRQ 1705.9 
  
-- -- 
  
-- 
  
The results obtained from kinase-specific phosphorylation prediction algorithms and in-
vitro kinase study shows that our strategy has successfully predicted known host-kinase/HIV-
protein interactions. For example, phosphorylation of Nef protein at Ser6 and Ser9 by protein 
kinase A (PKA) [133], phosphorylation Rev protein at Ser5 and Ser8 by casein kinase II (CK II) 
[150], and phosphorylation Vpu protein at Ser52 and Ser56 by casein kinase II (CK II) [151] 
were predicted using our strategy. Additionally, successful assessment of the known 
phosphorylation interaction between host-kinase and HIV-proteins, the result also demonstrates 
that our strategy also predicts some novel phosphorylation events in various HIV proteins. For 
example, our strategy has successfully predicted the phosphorylation of N-terminal of Vif 
protein with protein kinase C (PKC), and phosphorylation of N-terminal of Nef protein with 
protein kinase C (PKC) (results are shown in Table 3.5). 
3.4.3 Investigation of potential phosphorylation sites in HIV-1 structural proteins 
Our collaborator at MGH was interested in investigating potential cytotoxic T 
lymphocytes (CTL) phospho-epitopes in HIV proteins. The N-terminal of capsid (CA) protein (a 
protein derived from proteolytic cleavage of gag polyproteins) possesses a known CTL epitope, 
KF-11 (KAFSPEVIPMF) peptide. The in-silico prediction and preliminary studies performed at 
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MGH shown the presence of phosphorylation on Ser33, a residue presence in KF11 peptide. 
Hence, in our collaborative effort, we decided to investigate the potential host-kinase involved in 
phosphorylation of Ser33 residue of capsid protein. Similar strategic steps including multiple 
sequence alignments (results are shown in Figure 3.5 below) and kinase-specific phosphorylation 
prediction algorithms (Table 3.6) are utilized to identify the possible host-kinases for each 
potential phosphorylation sites across the capsid protein including the Ser33. 
 
Figure 3.5 Multiple sequence alignment of Capsid protein: Capsid (p24) protein sequences from different 
strains are aligned together using ClustalW software identifies well-conserve phosphorylation motif in 
Capsid protein across different strains. The residues which can be phosphorylate, such as Serine (S) and 
Threonine (T) are highlighted in yellow and green color respectively. 
 
 
Table 3.6 Phosphorylation prediction sites with potential kinases: data obtained from various kinase-
specific phosphorylation prediction algorithms such as NetPhosK, GPS and KinasePhos are combined 
and used to predict potential phosphorylation sites and possible kinases. 
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The previous publication by Cartier et al. identified three phosphorylation sites across the 
capsid protein, which includes Ser109, Ser149 and Ser178. The result shows although capsid 
protein plays a vital role in formation of the viral core structure and assembly, these 
phosphorylation events occurred in capsid protein do not affect its function in viral structure and 
assembly formation. In contrast, site-directed mutagenesis study showed that these three mutant 
viruses were able to assemble and bud but were unable to infect the cell due to incomplete 
reverse transcription. Hence, these results indicate phosphorylation events are essential for 
reverse transcription process of virus and viral infectivity [152].  
Because all three major phosphorylation sites (Ser109, Ser149, and Ser178) have been 
identified in previous investigation are present in C-terminal of capsid protein and our specific 
interest was to investigate phospho-epitope (KF11) presents in N-terminal of the capsid protein, I 
decided to investigate potential phosphorylation sites in the N-terminal of the capsid protein. As 
a preliminary goal of investigation was to identify host-kinases responsible for phosphorylation 
of Ser33 residue from CTL epitope, KF11, all predicted kinases from phosphorylation prediction 
algorithms (shown in Table 3.7) were evaluated by performing in-vitro kinase assays. Three 
overlapping peptides containing Ser33 residue were chosen for in-vitro kinase assay. 
Table 3.7 List of overlapping capsid peptides containing Ser33 residue 
 
 
The result of the in-vitro kinase assay of these capsid peptides shows phosphorylation of 
Gag-B22 peptide when incubated with p38 MAPK. Furthermore, none of the other capsid 
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peptides in presence of any of the above predicted kinases were shown to be phosphorylated 
(result not shown). The time-dependent increase in phosphorylated peptide mass peak 
(2215.36Da) with mass difference of +80 m/z (represent covalent addition of HPO3) from 
unphosphorylated peptide peak was observed. The mass spectra of the time-dependent kinase 
assay (1/2 hr, 1hr, 3hrs and overnight) are shown in Figure 3.6 below. Moreover, the 
phosphorylation of Ser33 residue by p38 MAPK indeed support the applied strategy as p38 
MAPK was predicted by all three prediction tools. The consistency in the results between in-
vitro kinase study and predicted host-cell kinase/HIV-phosphorylation site interaction 
demonstrates the efficiency of our applied strategy.  
 
Figure 3.6 Mass spectra of Gag-B22 peptide (WVKVVEEKAFSPEVIPMF- 2134.12Da) in presence of 
p38 MAPK and ATP at different time points (1/2hr, 1hr, 3hr, and overnight) are shown here. Time-
dependent increase in the mass peak at 2214.36Da shows the p38 MAPK-dependent phosphorylation of 
Gag-B22 peptide. 
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3.5 In-vitro kinase assay on HIV-proteins (Vif, Nef and CA) 
The in-vitro kinase assays were performed on HIV-derived peptides to find out lead 
kinase responsible for phosphorylation of individual HIV-protein for the further study. Based on 
the presence of a significant phosphorylation in in-vitro kinase assay performed on HIV-derived 
peptides, we concluded to investigate following host-kinase/HIV-protein interactions: 1) Vif 
protein in presence of protein kinase C (PKC), 2) Nef protein in presence of protein kinase A 
(PKA), and 3) Capsid protein in presence of p38 MAPK. The in-vitro kinase assays on the HIV- 
proteins (Vif, Nef and P24) were performed following similar protocol by incubating them with 
lead kinase and ATP for 4 hrs. After incubation with kinase, the protein was subjected to SDS-
PAGE gel followed by in-gel digestion by specific protease. The extracted peptides were directly 
subjected to peptide mapping and phosphorylation site analysis using MALDI-LTQ. Importantly, 
various proteases cleave at different sites, such as Trypsin is known to cleave C-terminal end of 
Lysine (K) and Arginine (R), chymotrypsin is known to cleave C-termini of phenylalanine (F), 
tryptophan (W) and tyrosine (Y), and Glu-C is known to cleave C-termini of Glutamic acid (E) 
residue in the protein sequence. Our efforts to characterize the phosphorylation interactions 
observed in the host kinase/HIV-peptides at the protein level have not shown any success yet. 
Various proteases such as Trypsin, Glu-C and chymotrypsin were employed (following in-gel 
digestion protocol suggested by vendor) to investigate phosphorylation sites in HIV-proteins. 
3.6 Summary and future direction 
 In this project, the preliminary goal was to identify one or more phosphorylation sites 
across HIV proteins and study the influence of identified phosphorylation event on HIV 
infection. This study implemented phosphorylation predictions algorithms, not just to sort out the 
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list of the potential phosphorylation sites across various HIV proteins but also to identify the 
kinases with high prediction scores. The prediction results of these algorithms authenticate our 
approach by successfully predicting few known host-kinase/HIV protein interactions. Results of 
the in-vitro kinase assay performed on potential phosphorylation sites containing HIV-peptides 
have identified a few novel interactions between host-kinases/HIV phosphorylation substrates. 
These include the interactions of phosphorylation sites of Vif, Nef and Capsid proteins with 
protein kinase C (PKC), protein kinase A (PKA), and p38 MAPK respectively.  
To achieve our projected aim, there are several steps can be taken in future.1) 
Identification and evaluation of potential phosphorylation sites from HIV structural proteins 
(Gag, Pol, and Env). 2) Study the kinase assay of HIV proteins using specific kinases obtained 
from initial screening on HIV peptides. Although few attempts have been made so far, various 
other approaches like a utilization of different proteases for protein digestion, optimization of in-
gel digestion protocol and in-solution digestion will be attempted. 3) The western-blot study of 
kinase treated HIV-protein using site-specific antibody will be performed to evaluate 
phosphorylation of HIV-protein. 4) Site-directed mutagenesis experiments of phosphorylation 
sites to Ala (Ser/Thr sites) and Phe (Tyr sites) will be performed to investigate effect of 
phosphorylation state on function or stability of the HIV-protein. 5) Biochemical effects of 
phosphorylation will be investigated by assessing the difference in activity of HIV- proteins as a 
function of phosphorylation state that will confirm biological relevance of identified in-vitro 
sites. This study will create a definitive database of host-cell kinase/HIV-phosphorylation 
substrates interaction and might provide better insight into intriguing cellular processes of HIV-1 
virus life cycle. 
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4.A.1 Background 
Proteolytic enzymes, also called as proteases or peptidases catalyze the hydrolysis of 
various protein substrates. Proteases are found in almost all living organisms including 
mammals, viruses, bacteria, plants and fungi [153]. The hydrolysis of protein substrates depends 
on several factors including, protease specificity, accessibility of susceptible peptide bond in 
protein substrate, and endogenous protease inhibitors [154]. The human genome expresses more 
than 670 proteases, categorized in 4 distinct classes based on their catalytic residues: serine 
proteases (31%), cysteine proteases (25%), metalloproteases (33%), and aspartic proteases (4%) 
[155]. In addition to these, there are also threonine proteases and few newly evolved proteases 
with unknown mechanism. More information about various proteases including newly 
discovered proteases can be found on the online database, MEROPS [156].  
In 1937, papain was the first cysteine protease isolated and characterized from Carica 
papaya [157]. The word “cathepsin” was derived from the Greek word kathepsein, which means 
“to digest” [158]. There are eleven members of cysteine cathepsin expressed in the human 
genome- cathepsin B, L, K, S, V, F, W, H, Z/X/P, C/J/dipeptidyl peptidase I, and O. The cysteine 
cathepsins play essential role in many physiological processes associated with the lysosome such 
as, like cell death, collagen degradation, protein degradation, and immune response [159, 160]. 
Aberrant expressions of cysteine cathepsins are responsible for many pathological disorders 
including, bone loss, autoimmune disease, metabolic syndrome and metastatic cancer [161-164]. 
As cysteine cathepsins can potentially serve as therapeutic targets, development of their 
inhibitors is crucial.  
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4.A.2 Structure of cysteine cathepsins 
Cysteine cathepsins are generally expressed in preproenzymes form, which have three 
major compartments- a signal peptide, a propeptide and a catalytic domain [165].  
 
Figure 4.1- Cysteine cathepsins- Structural compartments of preproenzyme forms 
 
Signal peptides consist of 10-20 amino acid residues and are involved in translocation into 
endoplasmic reticulum during mRNA translation [166]. Propeptides, generated by removal of 
signal peptide, are of variable length such as, 36 amino acids in human cathepsin X and 251 
amino acids in cathepsin F [167]. Propeptides are known to function- (1) as scaffolds for protein 
folding of the catalytic domain [166]. (2) as chaperones for the transport of proenzyme to 
lysosomal compartment following mannose-6-phosphate receptor (M6PR) pathway [166]. (3) as 
high-affinity reversible inhibitors to prevent premature activation of catalytic domain [168]. The 
length of catalytic domains of human cathepsins is 214-260 amino acid residues (Figure 4.1).  
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The first crystal structure among the cathepsins, that of cathepsin B, was determined in 
1990 [169]. This was followed by determination of crystal structures of cathepsin L [170], K 
[171, 172], H [173], x [174], V [175], C [176, 177], S [178] and F [179]. The crystal structures 
of cathepsin O and W are still not yet determined. Structural elucidation of cathepsins using 
cathepsin L as a typical representative is shown in Figure 4.2. 
                                 
Figure 4.2 Crystal structure of cathepsin L (PDB- 2YJC). The active site Cys25 and His163 are shown in 
ball-and-stick representation (purple color) 
 
It is composed of two main domains, referred to as the left (L) domain and right (R) 
domain. The L domain consist of three α- helices. The longest central helix is over 30 residues 
long. The R domain is β-barrel forming a coiled structure.  The active-site cleft formed at the 
interface of the both domains contains Cys25 (from L domain) and His163 (from R domain). 
These two catalytic residues form the thiolate-imidazolium ion pair that enhances nucleophilicity 
of the cysteine residue [180].  The propeptide binds to the active site cleft to prevent substrate 
binding [181, 182]. Evaluation of 3D- based sequence alignment of mature form of cysteine 
cathepsins exhibit the conservation of active-site residues- Cys25 and His163 (based on 
cathepsin L numbering) in addition to the residues interacting with main-chain of bound 
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substrate (Gln19, Gly68, and Trp183), the N-terminus Pro2 and certain Cys residues [183]. 
Although the three-dimensional structure of two human cysteine cathepsins, O and W, are still 
unresolved, a 3D sequence alignment performed independently using crystal structure of human 
cathepsin L as a template shows the same conservation pattern [184]. 
4.A.3 Substrate binding 
Schechter and Berger [185], originally proposed a nomenclature for the positions of the 
substrate residues (P) and the subsites of cathepsin (S) to understand and elucidate the 
interactions between cysteine cathepsins and their substrates. The positions (P) and subsites (S) 
were numbered in both direction of the scissile bond such as position P1 and P1’. The non-
primed side refers to the N-terminal part and primed side refers to C-terminal part of the 
substrate. Berger et al. observed that longer than 7 residues of peptides does not affect the 
kinetics of their degradation and concluded that there are seven substrate residues binding into 
seven subsites from S4 to S3’ as shown in Figure 4.3A [185]. Turk et al. revised nomenclature of 
substrate binding using insight provided by the crystal structures of cathepsin complexes with 
small-molecule and concluded five substrate residues bind to five subsites from S3 to S2’ as 
shown in Figure 4.3B [186]. 
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Figure 4.3 A) Pictorial representation of substrate binding sites according to Schechter and Berger. 
Enzyme pockets have been assigned as “S” and substrate peptide binding to corresponding pockets have 
been assigned as “P”. B) Revised substrate binding to papain like cysteine proteases according to Turk. 
This demonstrate the active site cleft binding residues contribution from L- domain as well as R-domain. 
 
The active-site cleft is composed of amino acid residues coming from L- and R-domains 
of cathepsins [187]. The L-domain provide the surface for the P3, P1 and P2’ residues, whereas 
the R-domain provide the binding surface for the P2 and P1’ residues [165]. The three-
dimensional structures of cathepsin have shown the substrate binding to active-site cleft in 
extended conformation. The active-site cleft of cathepsins include catalytic residues Cys and His, 
located onto two different domains. Further detailed study performed by evaluation of 
superposition of the structures indicates that there are only three well-defined substrate binding 
sites, S2, S1 and S1’. Among these substrate binding sites only S2 site forms a pocket, on the 
other hand S1 and S1’ subsites only offer binding surface [189].   
Depending upon the cleavage site, cathepsins have been further classified as 
endopeptidases, exopeptidases or both (Figure 4.1). An endopeptidase cleaves the peptide bonds 
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of nonterminal amino acids (i.e. within the molecule), in contrast to exopeptidases, which break 
peptide bonds from end-pieces of terminal amino acids. Among all the cysteine cathepsins, 
cathepsin K, S, L, V, and F exhibit predominantly endopeptidase activity, in which the active-
site cleft extends along the entire length of the two domains [166]. On the other hand, the 
exopeptidase cathepsins such as H, X and C, [166] are able to dock the substrates through their N 
or C termini and further classified based on, A) the termini of the substrate, and B) substrate 
peptide length they cleave. Cathepsin C is an aminodipeptidase [190], cathepsin H is an 
aminopeptidase [191] and cathepsin X is a carboxypeptidase [192]. Cathepsin B can exert both 
endo and exopeptidase activity. 
4.A.4 Localization, Regulation and Physiological Role 
Cysteine cathepsins have long been believed to be found in lysosome and are responsible 
for normal cellular protein degradation and turnover. Recent studies reveal the presence of 
cysteine cathepsins also in nucleus, cytoplasm, and in extracellular space [193]. The majority of 
cathepsins including, cathepsins B, H, L, X, V, F, O, and C are ubiquitously expressed in human 
tissues. Contrary to, cathepsins K, S and W show a restricted and tissue specific distribution. 
Cathepsin K is highly expressed in osteoclasts, epithelial cells, and synovial fibroclasts in 
rheumatoid arthritis joints [194]. Although cathepsin K, L, S, V, and B possess elastolytic and 
collagenolytic activities, cathepsin K is the only enzyme whose role in bone resorption has been 
well recognized in humans and mice [195]. Cathepsin S is predominantly expressed in 
professional antigen-presenting cell (APCs) including B-cells, macrophages and dendritic cells 
[196].  Cathepsin W is predominantly expressed in CD8+ lymphocytes and natural killer (NK) 
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cells [197, 198]. Cathepsin V, a homologue of cathepsin L precisely expressed in thymus, testis 
and cornea [199]. 
The activity of cysteine cathepsins are mainly regulated by A) zymogen activation, B) 
pH, and C) through their endogenous protein inhibitors [200]. Cysteine cathepsins show optimal 
activity at slightly acidic pH while becoming unstable at neutral pH. Hence cathepsins are 
irreversibly inactivated at neutral pH in the extracellular compartment [201]. Cathepsin S is the 
only cysteine cathepsin which is stable and active at neutral pH [202], while cathepsin L is the 
most unstable among cysteine cathepsins at neutral pH [203]. In the presence of high ionic 
strength and organic solvent content, cathepsin B irreversibly loss the activity in addition to 
structural changes [204]. Moreover, endogenous cathepsins inhibitors such as stefins control the 
activity of cathepsins in intracellular compartment; on the other hand, cystatins and kininogens 
control the activity of cathepsins in extracellular compartment [186]. Hormones and 
inflammatory cytokines play a key role in regulation of cathepsins B, K, L and S expressed in 
macrophages, cardiovascular and valve cells [205].   
These differential tissue distributions of specific cathepsins refer to their more explicit 
role in various physiological processes. For example, cathepsin K, B, V, S and L are responsible 
for degradation of various extracellular proteins such as laminin [206], fibronectin [206, 207], 
elastin [208, 209] and collagens [206, 210-212]. Cathepsin F, L, S and V are involved in antigen 
processing and degradation of MHC class II-associated professional antigen-presenting cells 
such as macrophages and dendritic cells [213-216]. The lysosomal cysteine cathepsins B, K, L, 
and H target the antiapoptotic molecules such as Bcl-2, Bcl-xL, and Mcl-1 in human cancer cells 
[217]. Cathepsin B, L, K, and S are involved in degradation of thyroglobulin at pH 7.4 and under 
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oxidative conditions [218]. Thus, recent studies revealed the role of cysteine cathepsins in 
various physiological processes beside protein degradation which include keratinocyte 
differentiation, prohormones activation, angiogenesis, neurobiology, bone remodeling, and 
immunological responses. [200, 219-222].  
4.A.5 Pathophysiology 
The over-expression and upregulation of cysteine cathepsins play key roles in many 
pathophysiological disorders, such as, neurological disorders, cardiovascular diseases, obesity, 
inflammatory diseases like rheumatoid arthritis, and cancer [223-228]. Under normal physiology, 
cysteine cathepsins activities are well-regulated in extracellular compartments by neutral pH, 
endogenous inhibitors including stefins, cystatins, kininogens, and thyropins, and reducing 
environment. However, acidification of extracellular compartments as well as reduction in 
concentration of endogenous inhibitors can lead to aberrant expression of cathepsins [166]. 
Increased expression of cathepsins L, K, S and V lead to degradation of extracellular 
matrix. Cathepsin K exhibit strong elastolytic activity at neutral pH and collagenolytic activity at 
slightly acidic pH [229]. While cathepsin V is known for its highest elastolytic activity among 
cysteine cathepsins [230]. Cathepsin B, S, L, K and H upregulation has been shown in mouse 
models of IL-13-stimulated chronic obstructive pulmonary disease [COPD] as well as in few 
other inflammatory conditions such as emphysema, silicosis, and sarcoidosis [231-233]. Several 
studies demonstrate the role of cathepsin L, S and K in obesity, which is an important risk factor 
for various cardiovascular and metabolic disorders [234, 235]. The effectiveness of cathepsin K 
inhibitors in the treatment of rheumatoid and osteoarthritis, atherosclerosis and other bone 
cancers indicate the critical role of cathepsin K in extracellular matrix degradation [236, 237]. 
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While cathepsin S, B, K and L contribute to cartilage destruction and immune response, aberrant 
activity of these cathepsins can lead to immune disorder such as rheumatoid arthritis [238-241]. 
Genetic disorders such as Haim-Munk and Papillon-Lefevre syndrome are associated with 
cysteine cathepsin C [242], and pycnodysostosis [243] is associated with cathepsin K.  
The association of cathepsin B in tumor progression was first documented 35 years back 
[244]. Now many studies have shown the elevated cathepsin expression and/or activity 
associated with cancer progression in number of several types of tumors such as, breast, skin, 
ovarian, brain, pancreatic, colorectal [245, 246]. Cathepsins B, L and S promote the migration 
and invasion of tumor cells [247, 248] through ECM degradation and initiation of proteolytic 
cascade that activate urokinase-type plasminogen activator, matrix metalloproteinases and 
plasminogens [165]. E-cadherin, a vital adherens junction protein, required to maintain cell to 
cell adhesion in epithelial cell lines is targeted to proteolysis by cathepsins B, L and S [249]. 
Hence, loss of E-cadherin leads to cell invasion and metastatic behavior of the cancer cells. Thus, 
development of an effective inhibitor for the cysteine cathepsins can potentially reverse the 
functional loss of E-cadherin and can be anticipated to reduce the metastatic behavior of solid 
tumors [250].  
4.A.6 Known cathepsin inhibitors 
The discovery of epoxysuccinyl-based inhibitor E-64 was very important for research on 
cysteine cathepsin inhibitors. Thereafter, due to the association of cysteine cathepsins in various 
pathological disorders including cancer, several cysteine cathepsin inhibitors have been studied 
in last few decades. Currently, a few selective inhibitors for cathepsin B, L, K, and S are under 
drug-discovery process. The molecules containing different electrophilic reactive groups to 
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interact with active site (nucleophilic cysteine residue) of cysteine cathepsins have been studied 
so far. The different reactive groups which have shown inhibition of cysteine cathepsin activity 
are- acyloxymethyl ketone [251], vinyl sulfone [252], nitriles [253], azapenone [254], thiadiazole 
[255], carbazate [256], epoxide [257], cyclopropenone [258], and furanone [259]. 
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4.B.1 Introduction 
Cathepsin B is probably one of the most studied cathepsin from the cysteine cathepsin 
family, due to its role in tumor progression, being highly expressed in a variety of malignant 
tumors [260]. However, only few of cathepsin B inhibitors have made their way to clinical trials 
[261]. Hence, the continuation of development and evaluation of cathepsin B inhibitor as an 
effective anti-cancer agent is essential. A cell-permeable small molecule inhibitory agent which 
offers covalent and irreversible interaction with Cys25, an active site of cathepsin B, could serve 
as a lead chemotypes for development of anti-neoplastic agents.  
This study was conducted at Dr. Sanjai Kumar’s lab (Queens College-CUNY). In our 
collaborative effort, we developed a library of compounds containing the sulfonyloxirane moiety 
and screened them to access their efficacy as a cathepsin B inhibitor in a time-dependent assay. 
A lead candidate evolved from this study, compound 5 (Figure4.4), which was further evaluated 
using enzymology and mass spectrometry-based experiments to study the type of interaction 
involved between compound 5 and active site, Cys25, of cysteine cathepsin B. In-vivo studies 
including intracellular inhibition of cathepsin B as well as inhibition of cell migratory behavior 
of highly metastatic breast carcinoma MDA-MB-231 cells demonstrate the effectiveness of 
compound 5 as a cathepsin B inhibitor. 
 
 
Figure 4.4 Chemical structure of compound 5- a lead cathepsin B inhibitory molecule 
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4.B.2 Development of library of cathepsin B inhibitory agents 
E-64, an epoxysuccinyl-based inhibitory agent, is known as a universal inhibitor of 
cysteine cathepsins. The structural investigation of the E-64-cathepsins complex assisted the 
development of selective cysteine cathepsin B inhibitors (e.g., CA030 and CA074) [262, 263]. 
The evaluation of the structures of CA030 and CA074 in complex with cysteine cathepsins 
revealed that there exist well-defined binding pockets, S2 and S1’, surrounding the S1 site 
(Schechter and Berger nomenclature) [183] that prefer aromatic hydrophobic groups [261, 263]. 
 
Figure 4.5 Origin of arylsulfonyl- substituted oxiranyl moiety 
 
Therefore, we hypothesized that an arylsulfonyl-substituted oxiranyl moiety could serve 
as a small molecule covalent inactivator of cysteine cathepsins. This approach envisions that (a) 
an appropriate binding of inhibitory compounds within the active site of cysteine cathepsin will 
allow the reactive Cys residue to be entrapped by the activated sulfonyloxirane group, (b) the 
sulfonyl group will likely mimic the potential H-bonding interactions that the carbonyl group α 
to the epoxy moiety exhibits in the inhibited CA030-cathepsin B complex [262] and (c) the 
sulfonyl group will further enhance the electrophilicity of the oxiranyl carbon, compared to a 
carbonyl group, thereby facilitating the entrapment of the active site Cys residue.  
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Different moieties of sulfonyloxiranes were synthesized following different synthesis 
protocols-1) Reaction of corresponding aldehyde in presence of potassium hydroxide and 
chloromethyl phenyl sulfone to yield sulfonyl oxirane (Scheme 4.1A) [264].  
 
Scheme 4.1 Various synthetic approaches in the development of cysteine cathepsin inhibitors 
 
2) Reaction of substituted thiophenol with 2-bromoethanol in presence of potassium hydroxide 
under reflux condition yield to arylthioethanol. The arylthioethanol is oxidized by hydrogen 
peroxide (30%) to provide 2-hydroxy arylsulfonylethane. Treatment of 2-hydroxy 
arylsulfonylethane with mesyl chloride in presence of triethylamine at 0
ᵒ
C leads to 
arylsulfonylethene. Further conversion of alkene intermediate to aryl sulfonyloxirane was carried 
out using n-BuLi in presence of tert-butyl hydroperoxide (Scheme 4.1B) [265]. 3) The aryl 
sulfonylthiirane molecules were synthesized according to a previously published protocol 
(Scheme 4.1C) [266]. 
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Table-4.1 Library of inhibitory molecules synthesized to evaluate inhibition of cysteine cathepsin  
 
4.B.3 Results and Discussion 
Since overexpression of cathepsin B has been linked to breast, prostate, bladder, stomach, 
colon, cervix, ovary, bladder, lung, and thyroid cancers, cysteine cathepsin B was chosen as the 
initial target to evaluate the efficacy of synthesized inhibitory agents [267]. The initial screening 
was performed by incubating a fixed concentration of compounds 1–13 with cathepsin B under a 
pseudo-first order condition. A small aliquot of the incubation mixture was withdrawn at a fixed 
time interval to assess remaining cathepsin B activity in presence of cathepsin B substrate.  
Compounds 1 and 2, containing substituent at the second carbon of the oxirane ring were 
ineffective in cathepsin B inhibition, in addition to, a thiirane analogue, 13, that potentially 
contains a better leaving group thiolate (compared to alkoxide in 12). This again indicated that 
proper placing between arylsulfonyl group and the reactive oxirane group within the cysteine 
cathepsin active site was critically important for its inhibitory effect. Hence, development of 
94 
 
cathepsin B inhibitory agents was then focused on synthesizing analogues of 2-(arylsulfonyl) 
oxiranes and their functional variants. 
Among the synthesized cathepsin inhibitors, compound 5 was found to be most effective 
inhibitor of cysteine cathepsin B activity. Cathepsin B activity did not improve even after 
dilution of 5–inactivated cathepsin B complex indicated that the mechanism of inhibition was 
perhaps covalent and irreversible in nature (data not shown). To assess the inhibitory efficacy, 
inactivation experiments were performed at appropriate concentrations of compound 5 under 
pseudo-first order conditions. The experimental data thus obtained were analyzed using a simple 
two-step inhibition model:  
                            
where Ki represents the reversible equilibrium binding constant for the first step, and ki is 
the first order inactivation rate constant for the second irreversible step. The pseudo-first order 
rate constants of inactivation (kobs) were determined at appropriate concentration of 5 
([I]>>[cathepsin B]), and a Kitz-Wilson analysis was performed to fit the experimentally 
obtained data (Figure 4.6A). This procedure yielded the equilibrium binding constant (Ki = 86 ± 
3 μM) for the first equilibrium binding step, and the first order inactivation rate constant (ki = 
0.21 ± 0.01 min
-1
) for the second irreversible step.  
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Figure 4.6 A) Kitz-Wilson plot of 5-mediated cathepsin B inactivation kinetics. The data points are fitted 
to a line that yields (a) Ki = 86 ± 3 µM for the first equilibrium step of inhibitor binding, and (b) ki = 0.21 
± 0.01 min
-1
 for the first order inactivation rare constant. B) The rate of 5-mediated cathepsin B inhibition 
is decreased in the presence of leupeptin (40 nM:  blue line), a known competitive inhibitor of cathepsin 
B, compared to the control (5% DMSO: red line) 
 
4.B.3.1 Type of interaction and inhibition 
To determine the type of inhibition and inhibitory concentration of cathepsin B exerted 
by compound 5, time-dependent as well as concentration-dependent loss of cathepsin B activity 
in presence of compound 5 was studied (Figure 4.7).  In order to be an active-site directed 
inhibitor, the rate of 5-mediated cathepsin B inactivation reaction postulated to be subsided in 
presence of a known active site-directed cathepsin B inhibitor, leupeptin (Ki = 5 nM) [268]. 
Furthermore, alleviation of inhibition of cathepsin B by compound 5 in presence of leupeptin 
was observed, indicating that the compound 5 is an active-site directed irreversible inhibitor 
(Figure 4.6B).  
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Figure 4.7 A) Progress curves indicating a time-dependent loss of cathepsin B activity. Compound 5 was 
incubated with cathepsin B under pseudo-first order condition, and the progress curves were obtained at 
appropriate times of inactivation (red: 0 min, blue: 11 min, green: 17min, black: 25 min and pink: 41 min) 
using a chromogenic substrate Z-RR-para-nitroanilide. B) Concentration-dependent loss of cathepsin B 
activity with time. The points are experimental, and the lines joining them are fitted to obtain the pseudo-
first order inactivation rate constant (kobs) 
 
Furthermore, matrix-assisted laser desorption/ionization (MALDI) - mass spectrometry 
was also employed to study interaction between compound 5 and cathepsin B. Compound 5-
inhibited cathepsin B complex displayed a mass peak increment of 212.1 amu in singly charged 
state compare to the mass of cathepsin B itself (control). This increment in mass was consistent 
with the molecular weight of compound 5; indeed, represented the attachment of compound 5 
with cathepsin B protein (Figure 4.8). No further mass increase was observed even after 
prolonged incubation of 5 with cathepsin B. This result demonstrated that the mechanism of 
compound 5-mediated cathepsin B inhibition is covalent and irreversible in nature. 
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Figure 4.8 A mass spectrometric analysis of 5- inhibited cathepsin B complex. A mass difference of 
212.1 amu, consistent with molecular weight of 5 (212.1), is observed in singly charged 5-inhibited 
cathepsin B complex (lower panel) compared to uninhibited cathepsin B enzyme (upper panel). This 
experiment demonstrated that the mechanism of 5-mediated cathepsin B inhibition is covalent and 
irreversible in nature. 
 
4.B.3.2 Computational Analysis- 
The computational modeling studies were conducted to understand molecular interactions 
of compound 5 with cysteine cathepsin B by making required modification to CA073-cathepsin 
B complex. (PDB id- 2DC6). A molecular dynamic simulation (100 ps) was performed on the 
compound 5- cathepsin B complex and the trajectories of the molecular dynamics simulation 
were analyzed. There were few interesting interactions noted between compound 5 and active 
site region of cathepsin B (Figure 4.9). The O3 of sulfonyl oxygen formed a H-bond (3.4 Å) with 
the side chain of Gln23-Nε-a key oxyanion hole residue. Consequently, its O2 atom was engaged 
in a robust hydrogen bond interaction (2.8 Å) with a tightly-bound active site water molecule 
(Wtr12).  
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Figure 4.9 Stereoscopic view of the energy-minimized structure of the covalently modified 5-cathepsin B 
complex. The low pKa active site Cys29 residue is the site for 5-mediated covalent modification. For 
clarity, only the inhibitor 5 (yellow) and the key cathepsin B active site residues are shown. The key h-
bonding distances of 5 with cathepsin B are shown in green. The intramolecular h-bonding interactions 
among cathepsin B active site residues near the inhibitor binding are depicted in red (heavy atom h-bond 
donor and acceptor atoms cut off is 3.6 Å). The position of primed and non-primed binding pockets on 
the cathepsin B surface is shown in pink text with underline. 
 
The phenyl moiety of the inhibitor was found to be involved in a hydrophobic interaction 
with a non- polar patch containing Met196, Gly197, and Gly198 residues of S2 pocket. In 
addition, the ortho-ethyl group interacted with CH–π interactions with the aromatic side chains 
of Trp221 and His110 from S2’ pocket, albeit weakly [260]. Our modeling study suggests that 
ortho-substituted aryl groups containing a negatively charged group could prove to be selective 
inhibitory agents towards cathepsin B. Notably, cathepsin B owned to its unique structural 
feature that contains a flexible occluding loop, residues 104–126, potential interaction of 
inhibitory agent with His110 and/or His111 could result in enhanced selectivity and efficacy 
towards cathepsin B.  
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4.B.3.3 Selectivity 
The inhibitory efficacy of compound 5 towards cathepsin B was tested in presence of an 
external nucleophile, azide ion (1mM). The absence of substantial changes in inhibitory efficacy 
indicated that compound 5 is inert to external nucleophiles and covalently interacts with the 
active site of cathepsin B. To assess the selectivity of compound 5, various enzymes from 
cysteine cathepsins family were selected (Table-4.2).  
Table 4.2 Selectivity of inhibition of compound 5 towards cysteine cathepsins as assessed by the 2
nd
 
order enzyme inactivation rate constants. 
            
a
Calculated from the ki and Ki parameters obtained using Kitz-Wilson Analysis. 
b
Determined by 
measuring pseudo-first order rate constant of inactivation kobs first and dividing the kobs by the inhibitor 
concentration. 
c
NI: No apparent time-dependent inhibition even at concentration as high as 1mM during a 
1-hour inactivation reaction. 
The compound 5 inhibit cathepsin B 1.9-fold more selectively than the other two closely 
related cysteine cathepsin F and cathepsin S. Also, cathepsin D (aspartyl cathepsin) was weakly 
inhibited by compound 5, i.e.,1/38
th
 fold less compare to cathepsin B. The other enzymes that 
100 
 
utilize serine as a catalytic residue including cathepsin G and trypsin protease did not exhibit any 
signs of inhibition by compound 5. Previous reports suggested that 2- (arylsulfonyl)-oxiranes are 
modest inhibitors of protein tyrosine phosphatases (PTPs) [265]. Hence, the inhibition of 
prototypical PTP, hPTP1B, by compound 5 was evaluated but, PTPs was not inhibited by 
compound 5. Apparently, the presence of an ethyl group at the ortho position of 2-
(phenylsulfonyl) oxirane is significantly favored the strong and effective interactions with at the 
cysteine cathepsin active site. However, it is essential to decipher the three-dimensional structure 
of compound 5- cathepsin B complex to develop future inhibitory agents based on this moiety. 
4.B.3.4 Cell permeability 
Due to the presence of electron withdrawing, sulfonyl moiety in adjacent to oxirane ring, 
it was essential to evaluate the stability of compound 5 at physiological pH before it’s evaluation 
as a cell-permeable molecule. An NMR- based experiment was performed to evaluate the half-
life of compound 5 at physiological pH of 7.4.  The result from this study indicated that 
compound 5 is relatively stable at physiological pH of 7.4, as half-life of compound found to be 
3.6 hour (Figure 4.10) and ultimately can be evaluated for in-vivo applications.  
Many of the recent reports suggested the presence and vital role of cysteine cathepsins in the 
compartments beyond lysosomes such as the cytoplasm, nucleus, mitochondrial matrix and 
plasma membrane [270-272]. For example, overexpression and an enhanced proteolytic activity 
of cytoplasmic cysteine cathepsins is responsible for tumor progression [224], while successful 
inhibition of cysteine cathepsins decelerate the tumor growth [273]. These reports highlight the 
quest for non-peptidyl and cell permeable small molecule inhibitors for cysteine cathepsins. 
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Figure 4.10 Estimation of the half-life of compound 5 at physiological pH 7.4. The relative peak intensity 
of 5 was plotted against time and data was fitted to a signal exponential. The t1/2 was estimated to be 3.6 
hours. 
 
To assess the intracellular efficacy of compound 5 against cathepsin B, the metastatic 
MDA-MB-231 human breast cell line was chosen since cathepsin B activity was known to be 
upregulated in these cells [274]. The efficiency in proteolysis of the well-established cathepsin B 
substrate, Z-RR-AMC (kcat/Km = 105 M
-1
 s
-1
) by cathepsin B, was evaluated to confirm the 
intracellular inhibitory efficacy of compound 5 [275, 276]. The result clearly implies the 
significant loss in cathepsin B proteolytic activity in the cell treated with compound 5 compare to 
control MDA-MB-21 cells (Figure 4.11A). Furthermore, dose-dependent inhibition of cathepsin 
B by compound 5 ratify not only the result from previous experiment but also cell-permeability 
of compound 5 (Figure 4.11B). 
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Figure 4.11 Effect of inhibitor 5 on cathepsin B activity in breast cancer MDA-MB-231 cells. A) Cells 
were incubated with vehicle (DMSO 0.1%) and 20µM of 5 for 20 min, followed by an additional 10 min 
of incubation with the substrate Z-RR-AMC (25µM net) of 5. Images show a significant loss of signal 
intensity (green) from the enzymatic turnover of the fluorophore cathepsin B substrate Z-RR-AMC 
(shown by red arrow in the bottom panel) at 20µM of 5. The control experiment without 5 indicates that a 
high level of substrate turnover occurs in these cells, thereby indicating a robust cathepsin B activity 
(white arrow- top panel). Scale bar= 10µm. B) The dose-dependent inhibition of intracellular cysteine 
cathepsin B activity with inhibitor 5 as measured by average fluorescence intensity over the entire cell. 
Note: The fluorescent intensity values are mean ± S.D. calculated over a population of at least 5-8 cells 
for each condition. *Statistical significance was evaluated by the Student’s t-test. 
 
Additionally, the inhibitory efficacy of compound 5 was also investigated using a 
proteolytic protein target of cathepsin B and S, namely E-cadherin [249]. E-cadherin plays a vital 
role in cell adhesion and cell morphology through maintaining intercellular contacts [277-279]. 
Complete or partial loss of E-cadherin occurs as tumor progressively becomes malignant [280-
282]. This observation directly associates the loss of E-cadherin to invasive migratory behavior 
of cancer cells [283, 284]. 
Due to the presence of low-level of E-cadherin in MDA-MB-231 breast cancer cells 
[282], this cell line was chosen to investigate the change in the level of E-cadherin using E-
cadherin antibody in presence and in absence of compound 5. As anticipated, a dose-dependent 
increase in the levels of E-cadherin was observed in a population of 5-treated MDA-MB- 231 
cells, as compared to control cells treated only with DMSO (Figure 4.12A and 4.12B). Although, 
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the overall cellular morphology of MDA-MB-231 cell line has changed upon treatment of 
compound 5 (Figure 4.11A and 4.12A), further experiments will be required to understand 
change in morphology at molecular level. A Western blot analysis was conducted to evaluate the 
E-cadherin level in compound 5- treated MDA-MB-231 cells (data not shown). Collectively, 
these studies demonstrated inhibitory intracellular efficacy of compound 5 towards cysteine 
cathepsin B in the invasive MDA-MB-231 breast cancer cells. 
 
Figure 4.12 A physiological substrate of cysteine cathepsins, E-cadherin, enriched in 5-treated MDA-
MB-231 cells. A) E-cadherin expression levels as detected by immunofluorescence in MDA-MB-231 
cells. Cells were treated with control (0.1% DMSO) and cysteine cathepsin B inhibitor 5 (20µM) for 20 
min, fixed, and then stained for E-cadherin. Bright field and merged fluorescence images of E-cadherin 
(red) and nuclear stain Hoechst 33342 (blue signal) are shown. Green and yellow arrows show enriched 
E-cadherin level (red) near the cell periphery (green arrow) and perinuclear region (yellow arrow) 
respectively in 5-treated cell, compared to control (0.1% DMSO). Scale bar = 10µm. B) A dose-
dependent increase of E-cadherin expression levels from immunocytochemistry as measured by average 
fluorescence intensity over the cell-periphery. The fluorescence intensity values are Mean ± S.D. 
calculated over a population of 28 cells for each condition. *Statistical significance was evaluated by the 
Student’s t-test. 
 
Moreover, to demonstrate the functional relevance of cysteine cathepsin B inhibition by 
compound 5, reduction in cell migratory behavior in metastatic MDA-MB-231 breast cancer 
cells was evaluated. The cell motility assay was performed in presence of compound 5 (10 µM 
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and 20 µM) and in absence of compound 5. The result from this assay support that the compound 
5 effectively inhibit the cell migratory behavior of MDA-MB-231 cells in dose-dependent 
manner (Figure 4.13). 
                        
Figure 4.13 The effect of cysteine cathepsin inhibitor 5 on the cell-migratory behavior of metastatic 
human breast cancer MDA-MB-231 cells. The cell migration phenotype was reduced upon treatment of 
cells with compound 5 (10 and 20µM), compared to control (0.05% DMSO). Each reported change in 
area value is the average of triplicate measurements with the corresponding standard deviation value. 
 
4.B.4 Conclusion 
We have developed a new class of non-peptidyl and cell-permeable small molecule 
inhibitors of cysteine cathepsin B. The covalent interaction between compound 5 and cysteine 
cathepsin B was evaluated using mass spectrometric analysis. The inhibitory efficacy of 
compound 5 was found to be selective towards cysteine cathepsin B. The computational analysis 
utilized to demonstrate interaction of compound 5 with the active site Cys residue in addition to 
surrounding S1 and S2 pockets. The inhibitor 5 was shown to be relatively stable to hydrolysis, 
cell-permeable, and effective in inhibiting intracellular cysteine cathepsin B activity in metastatic 
105 
 
human breast carcinoma MDA-MB-231 cells. Finally, effectiveness of compound 5 in reducing 
the migratory behavior of the metastatic MDA-MB-231 breast cancer cell lines was also 
demonstrated. This class of inhibitory agents could provide the platform for development of 
activity-based probe of cysteine cathepsins in future. 
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Chapter-4 C 
Development of highly potent, cell-active cathepsin L inhibitors 
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4.C.1 Introduction 
Cathepsin L is a ubiquitously expressed lysosomal endopeptidase that is primarily 
involved in several physiological processes such as cell cycle regulation, immune response, and 
development of natural killer cells [285-287]. Overexpression and aberrant activity of cathepsin 
L has been reported in many instances in various human malignancies such as breast, ovarian, 
prostate, colon, head and neck carcinoma, lung and gastric cancers [288]. Cathepsin L is known 
to be responsible for degradation of various extracellular matrix (ECM) such as collagen, 
laminin, and fibronectin and subsequently promote metastatic behavior of cancer. Due to 
elevated level of cathepsin L along with its vital functionality in cancer progression crafts 
cathepsin L, as a potential therapeutic target for development of anti-cancer treatment [289]. 
To date, the role of cathepsin L is remained largely unknown at cellular context. 
Moreover, the contradiction in functions of cathepsin L has been reported in few instances. For 
example, Di Piazza et al. found that increased glioma cell death was associated with 
accumulation of cathepsin L in the cytosol and established the pro-apoptosis role of cathepsin L 
[290]. By contrast, Gocheva et al. suggested that reduced cathepsin L expression increases 
apoptosis [249, 288]. In addition, previous investigations also suggested role of cathepsin L in 
both bone growth [291] as well as bone loss processes [292]. According to recent studies, 
development of a suitable activity-based cathepsin L probe can be a powerful tool to decipher the 
role of cathepsin L at cellular level [293]. Hence, we opted to develop a inhibitor that possess 
specific characteristics such as cell permeability, selectivity towards cathepsin L, covalent 
irreversible mode of inhibition, and  non-basic nature for homogenous distribution in cell and has 
potential to be developed as a activity-based cathepsin L probe in this report. 
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4.C.2 Library of Cathepsin L inhibitory agents 
Interactions of inhibitory agents with both the active-site as well as with surrounding 
pockets (i.e. S1, S2, S1’, S2’) of cathepsin L are essential for potency and selectivity. Previous 
studies including molecular docking of gallinamide A accompanied by X-ray crystallography of 
cathepsin L revealed several strategically important sites of interactions [294-296]. In another 
related study, it was noted that an appropriate position of an aromatic moiety could perhaps form 
more effective inhibitory interactions with the S’ residues of cathepsin L [297]. In addition, a 
visual analysis of a covalent and reversible inhibitor, Z-Phe-Tyr-(O-tert Bu)-C(O)CHO, bound to 
cathepsin L indicated that a non-polar cluster from the S’ pocket, involve Trp189, Leu144, 
Ala138, and Gly139 residues, formed critically important binding interactions with the tert-butyl 
group [296]. Hence, we sought to first develop a ligand that contain an electrophilic warhead and 
an aromatic group which is suitable to interact with the prime site residues of cathepsin L active-
site. 
The vinylsulfonate ester moiety was preferred over vinylsulfone due to the following 
reasons: 1) The vinylsulfonate ester moiety has never been investigated as electrophilic warhead 
in contrast to vinylsulfone [252, 298]. 2) The vinylsulfonate ester moiety displays a far superior 
reactivity as a Michael acceptor than vinyl sulfones [299]. 3) we hypothesized that that an 
additional S–O bond present in vinylsulfonate ester (but not in vinylsulfone) could rightly place 
the functionalized aryl group into the S’ pocket of cathepsin L for optimal interaction. 
Subsequently, the determined inhibitory efficacy of phenyl vinylsulfonate towards cathepsin L 
was 3-fold higher than that of phenyl vinylsulfone. This result supports the strategy of targeting 
the S’ pocket and conclusively led to development and screening of various aryl vinylsulfonate 
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ester molecules. (Table-4.3). The 4-bromophenyl vinylsulfonate ester (Compound 1) was 
identified as the most effective aryl vinylsulfonate ligand.  
Table-4.3 List of all inhibitory agents containing vinylsufonate ester moiety 
 
Torkar et al. [251] recently reported Cbz-Phe-Leu-CONH2 (Figure 4.14) as a modest 
inhibitor (Ki = 14 mM) of cathepsin L. This compound is nonbasic and inhibits cathepsin L 
activity by presumably occupying the non-prime pockets (i.e. S1, S2, and S3). We postulated 
that a hybrid design that incorporated the key features of compound 1 and Cbz-Phe- Leu-CONH2 
could render a highly potent and selective inhibitor of cathepsin L. Thus KD-1 was conceived 
(Figure 4.14). 
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Figure 4.14 A hybrid-design approach in the development of highly potent time-dependent inhibitor 
(KD-1) of human cathepsin L. To generate KD-1, a competitive inhibitor Cbz-Phe-Leu-CONH2 of the 
modest potency (Ki = 14µM), known to target S1, S2, and S3 pockets of cathepsin L, is conjugated to a 
prime site (S’) - targeting inhibitory ligand 1 at its C-terminal. 
 
4.C.3 Synthesis 
Inhibitor KD-1 was synthesized using the following scheme: N-Boc- L-Leucinal (I) was 
synthesized by oxidation of N-Boc-L-Leucinol which was utilized for the next step without any 
further purification [300]. The compound (II) was synthesized from ethyl methanesulfonate by 
treating with diethyl chlorophosphate in presence of butyllithium and anhydrous [301]. Reaction 
of N-Boc-L-Leucinal (I) with compound (II) in presence of sodium hydride and anhydrous THF 
yielded Boc-protected leucine vinylsulfonates (III). In the following step deprotection of Boc 
group from compound (III) was conducted using 25% TFA and dichloromethane. The free amine 
synthesized from this step was coupled to commercially available Cbz-protected phenylalanine 
in presence of coupling agent, HCTU, to generate compound (IV). Treatment of compound (IV) 
with tetrabutyl ammonium iodide in acetone led to sulfonate salt which was utilized for the next 
step without any further purification. The sulfonate salt, thus obtained, was converted to sulfonyl 
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Scheme 4.2 Synthesis procedure of development of cathepsin L inhibitor- KD-1 
 
chloride in presence of triphenylphosphine. The intermediate sulfonyl chloride was treated with 
4-bromo phenol in presence of triethyl amine to obtain final compound KD-1. 
4.C.4 Result and Discussion 
Assessment of potency of KD-1 was performed by measurement of IC50 value. An IC50 
value of 3.6 ± 0.1 nM was observed, indicating excellent binding of KD-1 to cathepsin-L. 
Additionally, a dose-dependent experiment was conducted at various concentrations of KD-1 in 
the presence of cathepsin L, and its substrate and the progress curves were generated under 
pseudo-first order conditions ([KD-1]>>>[Cathepsin L]) (Figure 4.15). Analysis of the progress 
curve [251] revealed near diffusion-controlled inactivation kinetics (second order inactivation 
rate constant (kinact) = 4.3 x 10
6
 M
-1
s
-1
). Irreversible inhibition of cathepsin L by KD-1 was 
concluded due to lack of upturn of enzyme activity even after large dilution of inactivated 
reaction mixture (data not shown).  
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Figure 4.15 Concentration-dependent inhibition of cathepsin L by KD-1. Progress curves for cathepsin L-
catalyzed hydrolysis of fluorescent substrate, Z-Phe-Arg-(7-amino-4-methylcoumarin, in the absence and 
presence of appropriate concentration of KD-1. 
 
4.C.4.1 Selectivity 
Various cysteine cathepsins such as, L, K, B, S, and H were chosen, in addition to, an 
aspartyl cathepsin (cathepsin D), a serine cathepsin (cathepsin G), a protein tyrosine phosphatase 
(hPTP1b), and a serine protease (trypsin) to evaluate the selectivity of KD-1 inhibitory molecule. 
The second order inactivation rate constants were determined by conducting inactivation kinetics 
under pseudo-first order condition. The derived values of the second order inactivation rate 
constants (kintact) for different enzymes as mentioned in Table-3.5 clearly indicate the selectivity 
of KD-1 molecule towards cathepsin L. The measured relative selectivity factor (RSF) indicated 
13 and 100-fold selectivity towards cathepsin L compare to the two most closely homologous 
cysteine cathepsins S and K, while 44,000-fold selectivity compare to cathepsin B. Furthermore, 
113 
 
no reactivity was observed against other enzymes. Owning to this remarkable selectivity, KD-1 
was chosen for further evaluation as a cathepsin L inhibitory agent. 
4.C.4.2 In-vivo cathepsin L inhibition 
To evaluate KD-1, as a cathepsin L inhibitory agent in-vitro experiment including 
cathepsin L and collagen type I performed in absence and in presence of KD-1. The results show 
Table 4.4 Second order enzyme inactivation rate constant (kintact) of cathepsin L inhibitor KD-1 against a 
panel of closely-related enzymes. 
Relative Selectivity Factor (RSF) = kintact (Cathepsin L) / kintact (other enzyme); NI* = No Inhibition at 
0.1mM of KD-1 in 1 hour; NA** = Not Applicable. 
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the reduction in collagen type I degradation in presence of KD-1 (Figure-4.16A). Furthermore, to 
evaluate the cell permeability and in-vivo cathepsin L inhibitory activity of KD-1, metastatic 
breast cancer MDA-MB-231 cell line was chosen owing to its known characteristic of 
overexpression of cathepsin L [302]. 
A cell permeable fluorescent substrate of cathepsin L, Z-Phe-Arg-(7-amino-4-
methylcoumarin), was chosen to evaluate in-vivo cathepsin L inhibitory efficacy of KD-1. The 
loss of the green fluorescent emerging from enzymatic turnover of the substrate by cathepsin L, 
indicate successful inhibition of intracellular cathepsin L activity by KD-1 (Figure 4.16B). This 
experiment confirmed the ability of KD-1 to inhibit cathepsin L activity at intracellular 
environment. 
 
Figure 4.16 A) Inhibitor KD-1 protects a physiological substrate of cathepsin L, human collagen type I, 
from proteolytic degradation in vitro. The α, β, and γ bands of collagen I are shown by blue arrow (left). 
B) Effect of KD-1 on cathepsin L activity in a metastatic breast cancer cell line. MDA-MB-231 cells were 
incubated with (a) vehicle (DMSO 0.05%), and (b) KD-1 (750nM) overnight (22hours). Intracellular 
inhibition of cathepsin L activity was assessed by exposing the cell to a cell-permeable fluorogenic 
substrate, Z-Phe-Arg-(7-amino-4-methylcoumarin) (2 minutes). The signal intensity (green) that emerges 
from the enzymatic turnover of the fluorophore substrate (white arrow) is lost when inhibitor KD-1 is 
present. This experiment demonstrates that KD-1 is cell permeable and is inhibiting intracellular 
cathepsin L activity in these cells. The results are representative of 3 independent experiments. Scale bars 
= 25µm. 
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4.C.4.3 Cell migration inhibition 
E-cadherin, an adherens junction protein vital for maintaining intercellular contacts and 
cellular morphology, is a proteolytic target of cathepsin L [249, 27-279]. The metastatic breast 
cancer MDA-MB-231 cell line express very low level of E-cadherin due to overexpression 
cathepsin L [282]. Hence to further evaluate the inhibitory efficacy of KD-1towards cathepsin L, 
the motility of MDA-MB-231 cells was determined (Figure 4.17). The substantial decrease in 
 
Figure 4.17 A) KD-1 reduces the migratory potential of highly metastatic MDA-MB-231 breast cancer 
cells, as assessed by the wound healing assays. MDA-MB-231 cells were grown overnight in a 6-well 
plastic dish before treating with DMSO (control, 0.05%) or KD-1 (750nM). After creating the wounds by 
drawing a pipet across a confluent field of cells, images were acquired at 0 and 22 hours. Representative 
images of three independent experiments are shown here. The dotted yellow lines indicate the edge of the 
wound at time zero, and the heights of the yellow arrows are indicative of wound width. B) The wound 
closure, a direct measurement of cell migratory potential, was calculated using the following equation: % 
wound closure = [(A0-A22)/A0] *100%, where A0 is the area of the wound measured immediately after the 
scratch, and A22 is the area of wound after 22 hours. The figure represents a statistical analysis from three 
independent experiments using the unpaired Student’s t test (ӿ, p<0.0001). The data were evaluated as the 
mean ± 1 standard deviation. The image analysis was performed by ImageJ software. 
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motility in KD-1 treated cell was observed. This result indicates enhanced integrity of cell-cell 
junctions due to maintenance of appropriate level of E-cadherin as a result of efficient cathepsin 
L inhibition by KD-1. 
4.C.5 Conclusion 
KD-1 is a highly potent, selective and cell-active inhibitory agent of cysteine cathepsin L. 
The inhibitory efficacy of KD-1 was found to be selective towards cysteine cathepsin L compare 
to the other closely related cysteine cathepsins such as cathepsin S, and K. The inhibition of 
collagen type I degradation by cathepsin L in presence of KD-1 in MDA-MB-231 cell indicate 
the suitability of KD-1 in biological context. Moreover, effectiveness of KD-1 in reducing the 
migratory behavior of the metastatic MDA-MB-231 breast cancer cell lines was also 
demonstrated. This inhibitory agent could provide the platform for development of activity-based 
probe of cysteine cathepsin L and help to understand many undefined roles of cathepsin L. 
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Contribution to the science community 
 My dissertation work emphasizes on to study covalent modification of different proteins 
and development of quantification method for small biological molecules using MALDI-Ion 
Trap mass spectrometry.  Although using advance technologies, expensive softwares and high-
end instruments, one can generate high quality data in a short-time, but it is less common to have 
these benefits at most of the research facilities and labs. The ultimate goal of this dissertation is 
not to compete against the advance instruments but to demonstrate qualitative and quantitative 
capability of MALDI- Ion Trap mass spectrometry and to provide viable alternative to the labs 
and facilities with limited resources. 
 In this dissertation, we have successfully demonstrated the application of MALDI-MS to 
identify and characterize various covalent modifications of proteins including phosphorylation 
and irreversible inhibition of host-enzymes using small molecules. In comparison to widely used 
LC-MS or LC-MS/MS, MALDI-MS mainly generates singly charged ions and therefore, 
interpretation of the mass spectra is simple. Furthermore, MALDI-MS exhibits a moderate 
tolerance to salts and other contaminants. Owing to these advantages, MALDI-MS offer simple 
and robust platform for the analysis of complex biological sample mixtures. The aim of the 
research project on HIV protein phosphorylation was to identify and characterize well conserved, 
potential phosphorylation sites of HIV proteins and to study the effect of phosphorylation in HIV 
infection and replication. This dissertation has successfully created database demonstrating 
interactions between HIV-auxiliary proteins/host-kinases. We strongly believe that this database 
will provide excellent platform to understand HIV cellular mechanism and may assist to identify 
novel strategic targets to develop anti-HIV therapeutic agents. 
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 The current dissertation also introduces a novel MALDI-MS
2
 based quantification 
methods for small biological molecules. In this work, we demonstrated that even though 
MALDI-MS has limited applications for quantitative analysis, it certainly offer few advantages 
over current quantification methods using LC-MS or LC-MS/MS. This novel MALDI-MS
2
 
based quantification method is not only cost-effective but also completes the analysis in short 
time with similar sensitivity. Additionally, as MALDI-MS has moderate tolerance towards salt 
and contaminants, this method can be applied to quantify the biomolecules in complex 
backgrounds such as serum and urine with prior purification or concentration of the sample. 
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S, Rizkalla S, Bastard JP, Rabasa-Lhoret R. Cathepsins in human obesity: changes in 
energy balance predominantly affect cathepsin s in adipose tissue and in circulation. 
Journal of Clinical Endocrinology & Metabolism. 2010; 95(4):1861-8. 
236. Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB, Sloane BF. 
Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. American Journal 
of Pathology. 2009; 175(3):1255-69. 
237. Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: 
rationale for the design of new therapeutics. Advanced Drug Delivery Reviews. 2005; 
57(7):973-93. 
238. Dejica VM, Mort JS, Laverty S, Percival MD, Antoniou J, Zukor DJ, Poole AR. Cleavage 
of type II collagen by cathepsin K in human osteoarthritic cartilage. American Journal of 
Pathology. 2008; 173(1):161-9. 
239. Schurigt U, Hummel KM, Petrow PK, Gajda M, Stöckigt R, Middel P, Zwerina J, Janik T, 
Bernhardt R, Schüler S, Scharnweber D. Cathepsin K deficiency partially inhibits, but does 
not prevent, bone destruction in human tumor necrosis factor–transgenic mice. Arthritis & 
Rheumatology. 2008; 58(2):422-34. 
149 
 
240. Svelander L, Erlandsson-Harris H, Astner L, Grabowska U, Klareskog L, Lindstrom E, 
Hewitt E. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and 
inflammation evoked by collagen-induced arthritis in mice. European Journal of 
Pharmacology. 2009; 613(1-3):155-62. 
241. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, 
Golenbock DT, Aoki K, Ohya K. Cathepsin K-dependent toll-like receptor 9 signaling 
revealed in experimental arthritis. Science. 2008; 319(5863):624-7. 
242. Toomes C, James J, Wood AJ, Wu CL, McCormick D, Lench N, Hewitt C, Moynihan L, 
Roberts E, Woods CG, Markham A. Loss-of-function mutations in the cathepsin C gene 
result in periodontal disease and palmoplantar keratosis. Nature Genetics. 1999; 23(4):421. 
243. Motyckova G, Fisher DE. Pycnodysostosis: role and regulation of cathepsin K in osteoclast 
function and human disease. Current Molecular Medicine. 2002; 2(5):407-21. 
244. Sloane BF, Dunn JR, Honn KV. Lysosomal cathepsin B: correlation with metastatic 
potential. Science. 1981; 212(4499):1151-3. 
245. Joyce JA, Hanahan D. Multiple roles for cysteine cathepsins in cancer. Cell Cycle. 2004; 
3(12):1516-9. 
246. Stoka V, Turk B, Schendel SL, Kim TH, Cirman T, Snipas SJ, Ellerby LM, Bredesen D, 
Freeze H, Abrahamson M, Brömme D. Lysosomal protease pathways to apoptosis cleavage 
of Bid, not pro-caspases, is the most likely route. Journal of Biological Chemistry. 2001; 
276(5):3149-57. 
247. Krueger S, Haeckel C, Buehling F, Roessner A. Inhibitory effects of antisense cathepsin B 
cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer 
Research. 1999; 59(23):6010-4. 
150 
 
248. Krueger S, Kellner U, Buehling F, Roessner A. Cathepsin L antisense oligonucleotides in a 
human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Therapy. 
2001; 8(7):522. 
249. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. 
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes & 
Development. 2006; 20(5):543-56. 
250. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the 
transition from adenoma to carcinoma. Nature. 1998; 392(6672):190. 
251. Torkar A, Lenarčič B, Lah T, Dive V, Devel L. Identification of new peptide amides as 
selective cathepsin L inhibitors: The first step towards selective irreversible inhibitors? 
Bioorganic & Medicinal Chemistry Letters. 2013; 23(10):2968-73. 
252. Mendieta L, Picó A, Tarragó T, Teixidó M, Castillo M, Rafecas L, Moyano A, Giralt E. 
Novel peptidyl aryl vinyl sulfones as highly potent and selective inhibitors of cathepsins L 
and B. ChemMedChem. 2010; 5(9):1556-67. 
253. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel 
DB, Lamontagne S, Léger S, LeRiche T, Li CS. The discovery of odanacatib (MK-0822), a 
selective inhibitor of cathepsin K. Bioorganic & Medicinal Chemistry Letters. 2008; 
18(3):923-8. 
254. Veber DF, Cummings MD. Structure-based design of cathepsin K inhibitors. Protein 
Crystallography in Drug Discovery. 2004:127-46. 
255. Leung-Toung R, Wodzinska J, Li W, Lowrie J, Kukreja R, Desilets D, Karimian K, Tam 
TF. 1, 2, 4-thiadiazole: a novel Cathepsin B inhibitor. Bioorganic & Medicinal Chemistry. 
2003; 11(24):5529-37. 
151 
 
256. Shah PP, Wang T, Kaletsky RL, Myers MC, Purvis JE, Jing H, Huryn DM, Greenbaum 
DC, Smith AB, Bates P, Diamond SL. A small-molecule oxocarbazate inhibitor of human 
cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection 
into human embryonic kidney 293T cells. Molecular Pharmacology. 2010; 78(2):319-24. 
257. Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamai M, Hanada K. L-
trans-Epoxysuccinyl-leucylamido (4-guanidino) butane (E-64) and its analogues as 
inhibitors of cysteine proteinases including cathepsins B, H and L. Biochemical Journal. 
1982; 201(1):189-98. 
258. Ando R, Sakaki T, Morinaka Y, Takahashi C, Tamao Y, Yoshii N, Katayama S, Saito KI, 
Tokuyama H, Isaka M, Nakamura E. Cyclopropenone-containing cysteine proteinase 
inhibitors. Synthesis and enzyme inhibitory activities. Bioorganic & Medicinal Chemistry. 
1999; 7(4):571-9. 
259. Fuller K, Lawrence KM, Ross JL, Grabowska UB, Shiroo M, Samuelsson B, Chambers TJ. 
Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human 
osteoclasts. Bone. 2008; 42(1):200-11. 
260. Sloane BF, Moin K, Krepela E, Rozhin J. Cathepsin B and its endogenous inhibitors: the 
role in tumor malignancy. Cancer and Metastasis Reviews. 1990; 9(4):333-52. 
261. Lampe CM, Gondi CS. Cathepsin B inhibitors for targeted cancer therapy. Journal of 
Cancer Science and Therapy. 2014; 6:417-21. 
262. Turk D, Podobnik M, Popovic T, Katunuma N, Bode W, Huber R, Turk V. Crystal 
structure of cathepsin B inhibited with CA030 at 2.0-. ANG. resolution: A basis for the 
design of specific epoxysuccinyl inhibitors. Biochemistry. 1995; 34(14):4791-7. 
152 
 
263. Yamamoto A, Hara T, Tomoo K, Ishida T, Fujii T, Hata Y, Murata M, Kitamura K. 
Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as 
determined by X-ray crystal analysis of the complex. Journal of Biochemistry. 1997; 
121(5):974-7. 
264. Arai S, Shioiri T. Asymmetric Darzens reaction utilizing chloromethyl phenyl sulfone 
under phase-transfer catalyzed conditions. Tetrahedron. 2002; 58(7):1407-13. 
265. Dana D, Das TK, Kumar I, Davalos AR, Mark KJ, Ramai D, Chang EJ, Talele TT, Kumar 
S. Design, Synthesis, and Evaluation of 2‐(arylsulfonyl) oxiranes as Cell‐permeable 
Covalent Inhibitors of Protein Tyrosine Phosphatases. Chemical Biology & Drug Design. 
2012; 80(4):489-99. 
266. Brown S, Bernardo MM, Li ZH, Kotra LP, Tanaka Y, Fridman R, Mobashery S. Potent and 
selective mechanism-based inhibition of gelatinases. Journal of the American Chemical 
Society. 2000; 122(28):6799-800. 
267. Kuester D, Lippert H, Roessner A, Krueger S. The cathepsin family and their role in 
colorectal cancer. Pathology-Research and Practice. 2008; 204(7):491-500. 
268. Knight CG. Human cathepsin B. Application of the substrate N-benzyloxycarbonyl-L-
arginyl-L-arginine 2-naphthylamide to a study of the inhibition by leupeptin. Biochemical 
Journal. 1980; 189(3):447-53. 
269. Brandl M, Weiss MS, Jabs A, Sühnel J, Hilgenfeld R. Ch⋯ π-interactions in proteins. 
Journal of Molecular Biology. 2001; 307(1):357-77. 
270. Dickinson DP. Cysteine peptidases of mammals: their biological roles and potential effects 
in the oral cavity and other tissues in health and disease. Critical Reviews in Oral Biology 
& Medicine. 2002; 13(3):238-75. 
153 
 
271. Abudula A, Rommerskirch W, Weber E, Günther D, Wiederanders B. Splice variants of 
human cathepsin L mRNA show different expression rates. Biological Chemistry. 2001; 
382(11):1583-91. 
272. Müntener K, Zwicky R, Csucs G, Rohrer J, Baici A. Exon Skipping of Cathepsin B 
mitochondrial targeting of a lysosomal peptidase provokes cell death. Journal of Biological 
Chemistry. 2004; 279(39):41012-7. 
273. Szpaderska AM, Silberman S, Ahmed Y, Frankfater A. Sp1 regulates cathepsin B 
transcription and invasiveness in murine B16 melanoma cells. Anticancer Research. 2004; 
24(6):3887-92. 
274. Krepela E, Vicar J, Cernoch M. Cathepsin B in human breast tumor tissue and cancer cells. 
Neoplasma. 1989; 36(1):41-52. 
275. Baricos WH, Zhou YO, Mason RW, Barrett AJ. Human kidney cathepsins B and L. 
Characterization and potential role in degradation of glomerular basement membrane. 
Biochemical Journal. 1988; 252(1):301-4. 
276. Hulkower KI, Butler CC, Linebaugh BE, Klaus JL, Keppler D, Giranda VL, Sloane BF. 
Fluorescent microplate assay for cancer cell‐associated cathepsin B. FEBS Journal. 2000; 
267(13):4165-70. 
277. Handschuh G, Candidus S, Luber B, Reich U, Schott C, Oswald S, Becke H, Hutzler P, 
Birchmeier W, Höfler H, Becker KF. Tumour-associated E-cadherin mutations alter 
cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene. 
1999; 18(30):4301. 
278. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during 
mesenchymal to epithelial reverting transition. Molecular Cancer. 2010; 9(1):179. 
154 
 
279. Wang F, Hansen RK, Radisky D, Yoneda T, Barcellos-Hoff MH, Petersen OW, Turley EA, 
Bissell MJ. Phenotypic reversion or death of cancer cells by altering signaling pathways in 
three-dimensional contexts. Journal of the National Cancer Institute. 2002; 94(19):1494-
503. 
280. Stemmler MP. Cadherins in development and cancer. Molecular BioSystems. 2008; 
4(8):835-50. 
281. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa 
ÂM, Simões-Correia J, Oliveira MJ, Pinheiro H. Epithelial E-and P-cadherins: role and 
clinical significance in cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 
2012; 1826(2):297-311. 
282. Wong AS, Gumbiner BM. Adhesion-independent mechanism for suppression of tumor cell 
invasion by E-cadherin. Journal of Cell Biology. 2003; 161(6):1191-203. 
283. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin 
promotes metastasis via multiple downstream transcriptional pathways. Cancer Research. 
2008; 68(10):3645-54. 
284. Nollet F, Berx G, Van Roy F. The role of the E-cadherin/catenin adhesion complex in the 
development and progression of cancer. Molecular Cell Biology Research 
Communications. 1999; 2(2):77-85. 
285. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: cellular roadmap to 
different functions. Biochimie. 2008; 90(2):194-207. 
286. Bylaite M, Moussali H, Marciukaitiene I, Ruzicka T, Walz M. Expression of cathepsin L 
and its inhibitor hurpin in inflammatory and neoplastic skin diseases. Experimental 
Dermatology. 2006; 15(2):110-8. 
155 
 
287. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, Villadangos JA, Ploegh H, 
Peters C, Rudensky AY. Cathepsin L: critical role in Ii degradation and CD4 T cell 
selection in the thymus. Science. 1998; 280(5362):450-3. 
288. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell 
Cycle. 2007; 6(1):60-4. 
289. Strojnik T, Kavalar R, Trinkaus M, Lah TT. Cathepsin L in glioma progression: 
comparison with cathepsin B. Cancer Epidemiology. 2005; 29(5):448-55. 
290. Di Piazza M, Mader C, Geletneky K, y Calle MH, Weber E, Schlehofer J, Deleu L, 
Rommelaere J. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing 
of cisplatin and TRAIL-resistant glioma cells. Journal of Virology. 2007; 81(8):4186-98. 
291. Potts W, Bowyer J, Jones H, Tucker D, Freemont AJ, Millest A, Martin C, Vernon W, 
Neerunjun D, Slynn G, Harper F. Cathepsin L‐deficient mice exhibit abnormal skin and 
bone development and show increased resistance to osteoporosis following ovariectomy. 
International Journal of Experimental Pathology. 2004; 85(2):85-96. 
292. Kakegawa H, Nikawa T, Tagami K, Kamioka H, Sumitani K, Kawata T, Drobnič-Kosorok 
M, Lenarčič B, Turk V, Katunuma N. Participation of cathepsin L on bone resorption. 
FEBS Letters. 1993; 321(2-3):247-50. 
293. Heal WP, Dang TT, Tate EW. Activity-based probes: discovering new biology and new 
drug targets. Chemical Society Reviews. 2011; 40(1):246-57. 
294. Miller B, Friedman AJ, Choi H, Hogan J, McCammon JA, Hook V, Gerwick WH. The 
marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of 
human cathepsin L. Journal of Natural Products. 2013; 77(1):92-9. 
156 
 
295. Chowdhury SF, Joseph L, Kumar S, Tulsidas SR, Bhat S, Ziomek E, Ménard R, Sivaraman 
J, Purisima EO. Exploring inhibitor binding at the S′ subsites of cathepsin L. Journal of 
Medicinal Chemistry. 2008; 51(5):1361-8. 
296. Shenoy RT, Sivaraman J. Structural basis for reversible and irreversible inhibition of 
human cathepsin L by their respective dipeptidyl glyoxal and diazomethylketone inhibitors. 
Journal of Structural Biology. 2011; 173(1):14-9. 
297. Chowdhury SF, Sivaraman J, Wang J, Devanathan G, Lachance P, Qi H, Ménard R, 
Lefebvre J, Konishi Y, Cygler M, Sulea T. Design of noncovalent inhibitors of human 
cathepsin L. From the 96-residue proregion to optimized tripeptides. Journal of Medicinal 
Chemistry. 2002; 45(24):5321-9. 
298. Palmer JT, Rasnick D, Klaus JL, Bromme D. Vinyl sulfones as mechanism-based cysteine 
protease inhibitors. Journal of Medicinal Chemistry. 1995; 38(17):3193-6. 
299. Reddick JJ, Cheng J, Roush WR. Relative Rates of Michael Reactions of 2 ‘-(Phenethyl) 
thiol with Vinyl Sulfones, Vinyl Sulfonate Esters, and Vinyl Sulfonamides Relevant to 
Vinyl Sulfonyl Cysteine Protease Inhibitors. Organic Letters. 2003; 5(11):1967-70. 
300. Blomberg D, Brickmann K, Kihlberg J. Synthesis of a β-strand mimetic based on a 
pyridine scaffold. Tetrahedron. 2006; 62(47):10937-44. 
301. Carretero JC, Demillequand M, Ghosez L. Synthesis of α, β-unsaturated sulphonates via 
the Wittig-Horner reaction. Tetrahedron. 1987; 43(21):5125-34. 
302. Zajc I, Sever N, Bervar A, Lah TT. Expression of cysteine peptidase cathepsin L and its 
inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines. Cancer 
Letters. 2002; 187(1):185-90. 
 
